Synergy Between Insulin-Like Growth Factor-I (igf-I) E-Peptides and Igf-I Signaling Alters Growth in Skeletal Muscle by Brisson, Becky Kathleen
University of Pennsylvania
ScholarlyCommons
Publicly Accessible Penn Dissertations
1-1-2012
Synergy Between Insulin-Like Growth Factor-I
(igf-I) E-Peptides and Igf-I Signaling Alters Growth
in Skeletal Muscle
Becky Kathleen Brisson
University of Pennsylvania, beckytatman@gmail.com
Follow this and additional works at: http://repository.upenn.edu/edissertations
Part of the Cell Biology Commons, Molecular Biology Commons, and the Physiology Commons
This paper is posted at ScholarlyCommons. http://repository.upenn.edu/edissertations/614
For more information, please contact libraryrepository@pobox.upenn.edu.
Recommended Citation
Brisson, Becky Kathleen, "Synergy Between Insulin-Like Growth Factor-I (igf-I) E-Peptides and Igf-I Signaling Alters Growth in
Skeletal Muscle" (2012). Publicly Accessible Penn Dissertations. 614.
http://repository.upenn.edu/edissertations/614
Synergy Between Insulin-Like Growth Factor-I (igf-I) E-Peptides and Igf-I
Signaling Alters Growth in Skeletal Muscle
Abstract
Insulin-like growth factor-I (IGF-I) is a potent growth factor that regulates and promotes growth in many
types of cells and tissues, including skeletal muscle. The igf1 gene encodes mature IGF-I and a carboxy-
terminal extension called the E-peptide. In rodents, alternative splicing and post-translational processing
produce two E-peptides (EA and EB). The mature IGF-I produced by both isoforms is identical, while EA
and EB share less than 50% homology. EB has been studied extensively and has been reported to promote cell
proliferation and migration independently of IGF-I and its receptor (IGF-IR) in culture, but the mechanism
by which EB causes these actions has not been identified. Further, the properties of EA have not been
evaluated. Therefore, the goals of this thesis were to determine if EA and EB possessed similar activity in
cultured myoblasts and in vivo, and if these actions are IGF-IR independent. In culture, we utilized synthetic
peptides for EA, EB, and a scrambled control to examine cellular responses. For an in vivo study, we injected
recombinant self-complementary Adeno-associated virus (AAVsc) vectors that express the IGF-I isoforms
mutated at Valine 44 to Methionine into mouse skeletal muscles. This mutation renders the IGF-I non-
functional, but the E-peptides are not affected. Both E-peptides increased MAPK signaling in culture and in
vivo, which was blocked by pharmacologic IGF-IR inhibition. Although the E-peptides did not directly induce
IGF-IR phosphorylation, the presence of either E-peptide increased IGF-IR activation by IGF-I, and this was
achieved in part through enhanced cell surface bioavailability of the receptor. EB increased myoblast
proliferation and migration and induced myofiber hypertrophy specifically in MHC2B fibers. Strangely,
expression of either E-peptide decreased the number of satellite cells. The proliferation and migration effects
were inhibited by IGF-IR signaling blockade and EB expression did not cause hypertrophy in MKR mice,
which do not express functional IGF-IR. Thus, in contrast to previous studies, we find that E-peptide
signaling, mitogenic, motogenic, and myogenic effects are dependent upon IGF-IR. We propose that the E-
peptides have little independent activity, but instead affect growth via modulating IGF-I signaling, thereby
increasing the complexity of IGF-I biological activity and regulation.
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ABSTRACT 
 
SYNERGY BETWEEN INSULIN-LIKE GROWTH FACTOR-I (IGF-I)  
E-PEPTIDES AND IGF-I SIGNALING ALTERS GROWTH IN 
SKELETAL MUSCLE 
Becky Kathleen Brisson 
Elisabeth R. Barton 
Insulin-like growth factor-I (IGF-I) is a potent growth factor that regulates and 
promotes growth in many types of cells and tissues, including skeletal muscle. The igf1 
gene encodes mature IGF-I and a carboxy-terminal extension called the E-peptide. In 
rodents, alternative splicing and post-translational processing produce two E-peptides 
(EA and EB). The mature IGF-I produced by both isoforms is identical, while EA and EB 
share less than 50% homology. EB has been studied extensively and has been reported to 
promote cell proliferation and migration independently of IGF-I and its receptor (IGF-IR) 
in culture, but the mechanism by which EB causes these actions has not been identified. 
Further, the properties of EA have not been evaluated. Therefore, the goals of this thesis 
were to determine if EA and EB possessed similar activity in cultured myoblasts and in 
vivo, and if these actions are IGF-IR independent. In culture, we utilized synthetic 
peptides for EA, EB, and a scrambled control to examine cellular responses. For an in 
vivo study, we injected recombinant self-complementary Adeno-associated virus 
(AAVsc) vectors that express the IGF-I isoforms mutated at Valine 44 to Methionine into 
mouse skeletal muscles. This mutation renders the IGF-I non-functional, but the E-
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peptides are not affected. Both E-peptides increased MAPK signaling in culture and in 
vivo, which was blocked by pharmacologic IGF-IR inhibition. Although the E-peptides 
did not directly induce IGF-IR phosphorylation, the presence of either E-peptide 
increased IGF-IR activation by IGF-I, and this was achieved in part through enhanced 
cell surface bioavailability of the receptor. EB increased myoblast proliferation and 
migration and induced myofiber hypertrophy specifically in MHC2B fibers. Strangely, 
expression of either E-peptide decreased the number of satellite cells. The proliferation 
and migration effects were inhibited by IGF-IR signaling blockade and EB expression did 
not cause hypertrophy in MKR mice, which do not express functional IGF-IR. Thus, in 
contrast to previous studies, we find that E-peptide signaling, mitogenic, motogenic, and 
myogenic effects are dependent upon IGF-IR. We propose that the E-peptides have little 
independent activity, but instead affect growth via modulating IGF-I signaling, thereby 
increasing the complexity of IGF-I biological activity and regulation. 
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 The goal of my research is to determine the roles of the E-peptides in skeletal muscle 
growth, to compare the activities of the different rodent E-peptides, and to determine if the E-
peptides act through IGF-IR signaling. 
IGF-I regulates pre and postnatal growth 
 Insulin-like growth factor-I (IGF-I) has endocrine and autocrine/paracrine activity and 
regulates pre- and postnatal growth in many tissues. The main source of IGF-I is the liver (92), 
which secretes IGF-I into the circulation. However, many cell types, including skeletal muscle, 
produce and respond to IGF-I. IGF-I expression is regulated by growth hormone secretion from 
the anterior pituitary gland (89), and circulates in serum bound to binding proteins, which affect 
IGF-I half-life, trafficking and availability (51). Free IGF-I promotes growth via binding to and 
activating its transmembrane tyrosine kinase receptor, IGF-I Receptor (IGF-IR). Upon IGF-I 
binding, IGF-IR autophosphorylates at several sites on its cytoplasmic tails, which initiates 
multiple signaling cascades, leading to increased growth, protein synthesis, and survival. 
 While embryonic development is predominantly regulated by another IGF, IGF-II (25), 
proper prenatal growth also relies on IGF-I signaling, as IGF-IR knockout mice die at birth, and 
IGF-I knockout mice rarely survive (60). The IGF-I null mice that do survive have diminished 
organismal growth (7), whereas mice over-expressing IGF-I systemically are 30% larger than 
controls (66), indicating that IGF-I signaling is also essential for normal postnatal growth.  
 While the endocrine function of liver IGF-I is important for prenatal development, it has 
become clear that local production of IGF-I controls growth in many tissues postnatally. The 
importance of local production of IGF-I was shown when liver-specific IGF-I knock-out mice 
were generated. These mice had no growth impairment, even though their serum IGF-I levels 
were 25% of normal (97, 107). Thus, the production of autocrine/paracrine IGF-I in tissues is 
sufficient for postnatal growth, and must be important for local growth regulation. 
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IGF-I drives skeletal muscle growth and repair 
  IGF-I is one of the major growth factors that directs skeletal muscle development, 
growth, and regeneration. When IGF-IR is specifically inactivated in skeletal muscle, muscles are 
10-30% smaller (32, 68) and exhibit delayed regeneration after injury (45). Increasing IGF-I in 
muscle by infusion of recombinant IGF-I (3), transgenic muscle-specific over-expression (20, 
72), or viral gene delivery (13), causes hypertrophy, can improve diseased muscle phenotype and 
function (11, 63), improves regeneration after injury (84, 91), and enhances the natural 
hypertrophy caused by resistance training (58). It is clear that IGF-I is a crucial growth factor in 
skeletal muscle that promotes hypertrophy and regeneration. 
 Growth and repair in mature skeletal muscle is a complicated process involving many 
cell types and growth factors, highly organized, and carefully timed (Figure 1-1). When muscle 
tissue grows during regular growth or with exercise, or when muscle is damaged by injury or 
overload, the muscle fibers must increase in size. This hypertrophy requires increases in protein 
synthesis, but increasing protein synthesis in skeletal muscle requires additional nuclei (4, 80). 
Since muscle fibers themselves are post-mitotic and cannot divide to provide the necessary 
nuclei, growth and regeneration relies on a stem cell-like niche of quiescent pre-muscle cells 
called satellite cells. Satellite cells are located between the basal lamina surrounding muscle 
fibers and the fiber cell membrane (67), and remain quiescent until needed for growth or repair. 
Once activated by growth signals, overload, or injury, the satellite cells proliferate, migrate to the 
region of the muscle that requires extra nuclei, and differentiate by fusing with myofibers (33). 
 Skeletal muscle growth and repair depends on IGF-I to stimulate the conventional 
pathways of muscle cell proliferation and differentiation in growth and repair (82, 83), leading to 
hypertrophy. IGF-I is upregulated in hypertrophic muscles and after damage or overload (2, 49), 
stimulates satellite cells (14), and increases protein synthesis in mature muscle fibers (14). 
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Muscle hypertrophy and the proliferation and differentiation of satellite cells in skeletal muscle 
has been directly linked to IGF-IR activation (53), and mice without active IGF-IR  in muscle 
display delayed differentiation (45). In addition, IGF-I expression increases in mechanically 
stimulated muscle, even when GH is not present, indicating that muscle stimuli alone can increase 
igf1 mRNA (26), linking muscle function with IGF-I activity. 
 IGF-I regulates muscle growth via binding to and activating IGF-IR, which initiates 
multiple signaling cascades (77) (Figure 1-2). The IGF-I ligand binds to the extracellular α-
subunits of the IGF-IR homodimer, leading to autophosphorylation at multiple tyrosines on the β-
subunits. The phosphorylated tyrosines recruit proteins containing insulin receptor substrate 
sequences (IRS). These proteins serve as docking sites for other proteins involved in downstream 
signaling pathways. IGF-IR activation triggers the mitogen-activated protein kinase (MAPK) 
pathway, which includes extracellular signal-regulated kinase 1 and 2 (ERK1/2), increasing 
proliferation and migration in satellite cells and myoblasts. The phosphoinositide 3-kinase, (PI3-
Kinase/Akt) pathway is also stimulated, which leads to increased differentiation and protein 
synthesis in mature muscle fibers (23, 50, 59). 
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Figure 1-1
 
 
Figure 1-1. Satellite cell activation, and myoblast proliferation, migration and 
differentiation. Normal satellite cells are quiescent, and reside outside of the muscle 
sarcolemma, but under the basal laminia. When a muscle is overloaded, injured, or signaled to 
grow naturally, satellite cells activate. They proliferate to create many myoblasts, which will be 
the source of the extra nuclei necessary for muscle repair. The myoblasts migrate to the sites of 
needed nuclei, and differentiate into muscle fibers by fusing with each other, or fusing with 
existing fibers. The myoblast nuclei provide the needed DNA and transcriptional and translational 
machinery necessary for growth, which requires an increase in protein synthesis.  
Satellite Cell Activation
Proliferation
Migration
Differentiation
 Figure 1-2 
 
Figure 1-2. IGF-IR signaling in skeletal muscle growth. 
tyrosine kinase receptor, IGF
sites on the intracellular β-subunits, leading to Insulin Receptor Substrate (IRS) proteins binding. 
IRS proteins form docking sites for different signaling pathways. Ras
MAPK pathway, leading to ERK1/2 phosphorylation and increases in proliferation. The PI3K 
pathway is also stimulated, leading to Akt phosphorylation and muscle hypertrophy, survival, 
increased protein synthesis, and myoblast 
6 
IGF-I binds to and activates its 
-I Receptor (IGF-IR). Activated IGF-IR autophosphorylates at many 
-IRS binding stimula
differentiation. Adapted from (77). 
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IGF-I protein processing  
 The general consensus is that all IGF-I activity is mediated by mature IGF-I, but the igf1 
gene encodes for more than solely the mature growth factor. The mature IGF-I polypeptide that 
circulates in the serum consists of 70 amino acids (85), but the igf1 gene codes for a longer pro-
protein. In the early 1980’s, it was proposed that IGF-I was synthesized as a precursor protein that 
requires proteolytic processing at both the N- and C-termini to produce mature IGF-I (48). The 
necessity for IGF-I precursor processing is similar to insulin, the protein from which IGF-I is 
named. Pro-insulin includes a 31-amino acid C-peptide, and after protein processing, this peptide 
is secreted from pancreatic β-cells (99). For IGF-I, the full-length precursor polypeptide is called 
pre-pro-IGF-I, and contains a signal peptide, mature IGF-I, and a C-terminal extention called the 
E-peptide (Figure 1-3). 
 At the N-terminus, IGF-I has a signal peptide, which is cleaved away from the remaining 
protein during translation in the ER (28). In addition, multiple groups have observed a mature 
IGF-I in vivo that is missing the first three amino acids (28, 35, 73, 90). Therefore, further 
proteolysis at the N-terminus of the mature IGF-I protein is possible.  
 The igf1 gene also encodes C-terminal E-peptide, called “E” because it follows the B-C-
A-D domains of mature IGF-I, named after the domains of insulin (100). Intact polypeptides 
including IGF-I and the E-peptide are called pro-IGF-I. The E-peptide begins at amino acid 71, 
which is a middle residue in an unique pentabasic prohormone cleavage motif Lys-X-X-Lys-
Arg71-X-X-Arg-X-X-Arg77 (29). Subtilisin-related proprotein convertases like furin, residing in 
the trans-golgi, cleave polypeptides that include this motif. Proprotein convertses can cleave pro-
IGF-I at both Arg71 and Arg76. The cleavage actually leaves the Arg attached to mature IGF-I, 
and thus a carboxypeptidase is then required to remove the remaining C-terminal Arg (29). The 
cleavage results in free mature IGF-I and an E-peptide (28-30) (Figure 1-3).  
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 In addition, pro-IGF-I has been found in cell culture media and in vivo in serum (12, 21, 
22, 79, 106), implying that some pro-IGF-I is not cleaved within the secretory pathway and that 
the E-peptide can be secreted out of the cell still attached to IGF-I. However, there is no evidence 
that the secreted pro-IGF-I is destined to be cleaved into mature IGF-I, as mixing pro-IGF-I with 
conditioned media containing naturally-secreted proteases does not cleave pro-IGF-I into mature 
IGF-I (29). So, it is unclear as to whether secreted pro-IGF-I is intended for its own activity, or as 
a source of mature IGF-I or E-peptides. 
 
  
 Figure 1-3 
 
 
 
Figure 1-3. IGF-I processing
pre-pro-IGF-I precursor protein that includes a signal peptide, signal peptide cleavage site, IGF
pro-protein convertase cleavage site, and E
removed from the remaining protein, now called p
trans-golgi separates the mature IGF
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igf1 splicing 
 Early studies examining the igf1 gene identified at least 2 different mRNA isoforms 
encoded by 6 exons (15, 86-88, 104). Alternative splicing gives rise to the different isoforms, and 
all igf1 isoforms are translated in vivo (34). Exons 1 or 2, and a portion of exon 3 encode the 
signal peptide; exons 3 and 4 encode mature IGF-I; and the remainder of exon 4, and exons 5 
and/or 6 encode the E-peptide (Figure 1-4). 
The 5’ end of igf1 mRNAs contains either exon 1 or exon 2. These exons encode the 
beginning of the signal peptide; thus two isoforms are possible: Class I, including exon 1, and 
Class II, including exon 2 (108). Class II is generally considered the endocrine form, as a higher 
percentage of liver isoforms include exon 2 (1). However, the splicing of these exons does not 
affect the amino acids for functional IGF-I protein. Additionally, the different signal peptides 
might be redundant, as exon 2 knock-out mice, which can only make Class I IGF-I isoforms, 
grow normally and have normal levels of IGF-I circulating in the serum and in tissues (102). 
 The critical splicing events that determine the pro-IGF-I isoform expressed occur at the 
3’ end of the igf1 gene, and this splicing event is somewhat different between rodent and 
human/primate isoforms. In the rodent and other non-primate mammals, there are two igf1 
isoforms called IGF-IA (IA) and IGF-IB (IB).  The difference in the isoforms is due to the 
exclusion (IA) or the inclusion (IB) of exon 5, a short 52-nucleotide cassette exon (15, 86) 
(Figure 1-4). The splicing only affects the E-peptide, and so the IGF-I from both isoforms are 
exactly the same, while IA isoforms give rise to E-peptide A (EA) and IB isoforms include E-
peptide B (EB) (Figure 1-4A). 
In humans, there are three possible E-peptides (Figure 1-4 B). Human exon 5 is much 
larger than in rodents, and includes a stop codon. Isoforms that include the entire exon 5 have a 
77-amino acid long E-peptide and are called “B” isoforms, because this isoform was identified 
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before the human homolog to rodent IB. Later, it was discovered that humans also had an isoform 
similar to rodent IB, in which both exons 5 and 6 are utilized, called “C”. Only 49 nucleotides 
from exon 5 are included due to use of a cryptic 5’ donor splice site, leading to a human E-
peptide (hEC) that is the human homolog of rodent EB, as they share 73% identity (18). Because 
this thesis mostly concerns the rodent isoforms, the rodent terminology will be used. IB = human 
IC/hIC. EB = human EC/hEC. 
 In all cases, the predominant IGF-I isoform produced is IA, which is the most conserved 
across all species examined (61, 62, 93, 94, 105). The IB/hIC isoform constitutes less than 10% 
of human (18) or rodent (61) IGF-I isoforms. 
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Figure 1-4 
 
 
Figure 1-4. igf1 transcript splicing. The igf1 gene is alternatively spliced at the 5’ and 3’ ends. 
Including exon 1 forms Class I signal peptides, while isoforms beginning at exon 2 are Class II. 
The importance of the two Classes of IGF-I signal peptides is unclear A. Rodent igf1 mRNA 
splicing at the 3’ end creates two isoforms: IA excluding exon 5, and IB isoforms, which include 
exon 5, leading to a frame-shift in exon 6, and an earlier stop codon. B. Human 3’ splicing leads 
to three isoforms. A novel isoform, human IB, includes the entirety of a large exon 5, which 
includes a stop codon. Human IC, which is 73% identical to rodent IB, contains only 49 residues 
in exon 5, then splices to exon 6. Adapted from (8).  
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Human EB: the novel E-peptide with mitogenic and anti-cancer activity 
 Since only the E-peptides differ between IGF-I isoforms, it was suggested that the E-
peptides themselves could have activity (94). The first work that investigated the possibility that 
the E-peptides may have a biological function focused on the unique human E-peptide, hEB (95). 
Using protein cleavage sequence analysis, it was predicted that hEB is processed into at least two 
peptides. One of these putative peptides, IBE1, would be formed after proteolytic cleavage and 
peptidyl C-terminal amidation. A recombinant IBE1 peptide increased proliferation in human 
bronchial epithelial cells. When a neutralizing antibody to IGF-IR was added to the proliferation 
assay, IBE1 could still induce proliferation, suggesting that IBE1 does not act through IGF-IR. In 
addition, IBE1 bound to a specific cell-surface binding site, but IBE1 binding was not abolished 
when IGF-I was added as a binding competitor, suggesting that IBE1 binds to a receptor that is 
not IGF-IR.  
 Years later, it was discovered that hEB localizes to nucleoli (101), induces neuroblastoma 
cell differentiation, and increases neurite growth and ERK1/2 phosphorylation (54). Recent data 
from our lab shows that full-length hEB increases proliferation and migration in multiple human 
cell lines (31). While it is understandable that early focus would be placed on a novel human 
peptide, it is curious that there have not been more studies on the biological activity of this 
peptide, in view that it has multiple interesting biological activities.  
 
Trout IGF-I Isoforms 
 In the early 1990’s, it was discovered that rainbow trout, Oncorhynchus mykiss, also has 
different IGF-I isoforms, leading to multiple E-peptides. These fish have four possible E-
peptides, and as they most closely resemble the mammalian EA peptide, they were named Ea-1, 
Ea-2, Ea-3, and Ea-4 (93). It was discovered that the isoforms were expressed at different times 
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during trout embryonic development (43), and that recombinant Ea-2, -3 and -4 increase 
proliferation in mouse fibroblasts, transformed human embryonic kidney cells, and human 
mammary gland tumor cells (103). These data were among the first to show that different E-
peptides, separate from IGF-I, could have activity in a variety of different cell lines. This also 
showed that in addition to affects on proliferation, Ea-2 and -4 decrease cancer colony formation, 
enhance cell attachment, and reduce invasive activity and morphological change (17). These 
results took E-peptide activity from simple proliferation enhancers, to factors affecting cancer 
growth and morphology.  
 Next, this group wanted to determine if the Ea-4 E-peptide had similar activity to the 
human EB E-peptide. They compared Ea-4 and hEB in neuroblastoma cell colony formation. 
Recombinant hEB and Ea-4 decreased colony formation, increased cell differentiation into 
neurons and increased neurite growth. Interestingly, they found that the increase in neurite growth 
depended on the MAPK and PI-3K pathways; pathways involved in IGF-I signaling (54). Later, 
they found that human EB and trout Ea-4 share a binding site that is different from where IGF-I 
and insulin binds (55), and further studies focused on Ea-4 and its inhibitory affects on cancer cell 
invasion (96) and embryonic development (16, 19). Alternative splicing of igf1 in trout increases 
the evidence that splicing is an important and conserved feature of igf1 expression. The trout E-
peptides have biological activity in many cell types from different species, suggesting that the E-
peptides have an important and conserved activity. 
 
Rodent IGF-IB/human IGF-IC: Mechano Growth Factor 
 Focus on the IB isoform, specifically in skeletal muscle, began in the late 1990’s when 
the lab of Geoffrey Goldspink investigated the expression of igf1 RNA in stretched rabbit 
muscles undergoing hypertrophy (109). They discovered that two isoforms were expressed. Both 
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isoforms increased after stretch, but one of the forms could only be detected after stretch. This 
form included exon 5, and thus was IB. Since the expression of IB was undetectable in normal 
muscle and upregulated after stretch in hypertrophic muscle, this form was considered 
responsible for muscle growth. Later they examined mouse muscles and found that this stretch-
induced isoform was absent in dystrophic muscle, even after stretch (42). This led to a patent, 
where Goldspink describes an igf1 splice variant from exons 4, 5, and 6 that is the mechanical-
stimulation-specific and stretch-inducible IGF-I isoform that induces growth of muscle tissue 
(40). 
 The Goldspink lab gave this stretch-induced isoform a new name: Mechano Growth 
Factor (MGF), to set it apart from liver isoforms, and put focus on its response to mechanical 
stimuli (69). They claimed that IA is the liver-type isoform and has a systemic endocrine action, 
even when expressed in non-liver tissues like muscle. MGF/IB, on the other hand, has an 
autocrine/paracrine function. In this study, rabbit extensor digitorum longus (EDL) muscles were 
stretched and electrically stimulated, and the expression of both isoforms increased after both 
stretch alone and stretch with electrical stimulation (an eccentric contraction, ECC) (69). 
 Since MGF is preferentially expressed in muscle undergoing hypertrophy, it seemed to 
have a function in promoting muscle growth. Muscle strength and igf1 expression decreases with 
age (56), and so the Goldspink group next looked at the affect of age on MGF expression after 
mechanical stimulation. Young and aged rats were subjected to a surgical overload model (74) 
and young and older humans were subjected to high-resistance exercise (44). In both experiments 
and age groups, the expression of IA did not increase significantly after the perturbation. 
Expression of MGF, on the other hand, did increase in young rats and humans, but this increase 
was dampened (74) or non-existent (44) in the older group. Interestingly, the expression of 
MyoD, which is turned on when satellite cells are activated, also increased in the young 
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populations. These data were the first to draw a possible connection between satellite cells and 
MGF expression, which would be the next focus of MGF research. 
 To study the timecourse of igf1 isoform expression changes and satellite cell activation, 
rats were subjected to ECC contractions or injected with bupivacaine, a myotoxin (46, 47). The 
expression of MGF increased quickly after injury and then declined (Figure 1-5 A), while IA 
expression peaked later and did not decline (Figure 1-5 B). With bupivacaine injury, MGF 
expression peaks at four days after injection, and IA peaked at 11 days (47). The increase in MGF 
expression occurred before the peak in MyoD or m-cadherin, an attachment protein associated 
with activated satellite cells, expression. Since MGF expression occurs before satellite cell 
activation markers are expressed, the authors claimed that MGF initiates satellite cell activation. 
To further investigate satellite cell growth, C2C12 myoblasts were transfected with plasmids 
containing MGF or IA cDNA (110), or treated with a synthetic MGF peptide including the 
residues from exons 5 and 6 only (synMGF). MGF increased myoblast proliferation, and delayed 
their differentiation into myotubes, a model for muscle fiber formation. 
 These studies have become the basis for the “MGF hypothesis” (65), which explains the 
timecourse of igf1 isoform expression and proposed activity in relation to muscle repair, satellite 
cell activation, and muscle formation (Figure 1-5 C). Soon after injury or overload, the expression 
of MGF increases. MGF then activates satellite cells, and stimulates their proliferation. MGF 
expression then quickly declines before fusion occurs, which is important because MGF delays 
muscle differentiation (110), and must disappear before the activated satellite cells fuse with 
muscle fibers. By this time, IA expression has increased, providing the IGF-I necessary for 
enhanced differentiation. This later increase in IA expression, leading to increased mature IGF-I 
protein, would increase protein synthesis in the myofibers over a longer timescale (46). 
Therefore, both isoforms lead to hypertrophy, but MGF is particularly important as it provides the 
activated satellite cells, which become the nuclei for new muscle fiber formation or repair. 
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 Once a role for MGF was established, studies looked at other skeletal muscle models to 
investigate aspects of MGF activity in specific muscle types, myoblasts, and satellite cells. The 
expression of igf1 isoforms in the levator ani, a muscle involved in childbirth, was investigated in 
the mothers after giving birth (24). Both IA and MGF expression increased after childbirth, and 
there was robust MGF staining in levator ani muscles after difficult births, which are associated 
with muscle damage. This verifies that MGF is involved with muscle injury and repair, even in 
non-limb muscles. While MGF increases the proliferation of myoblasts in culture, it was 
unknown if MGF had any other effects on satellite cells. Human myogenic cell migration 
increased after addition of synMGF (71), and synMGF improves myogenic precursor cell 
transplantation. Also, synMGF increases the proliferative lifespan and delays senescence in 
human satellite cell primary cultures obtained from young but not old humans (52), confirming 
that MGF is most active in young muscle, which splices more to MGF than older, wasting muscle 
(38). As with mouse myoblasts, synMGF increases cell proliferation (78) and delays 
differentiation (110) in human myogenic precursor cells (70), and in porcine satellite cells (81), 
confirming that MGF has similar activity in different species. Also, synMGF increases the 
proportion of human myogenic cells in normal and dystrophic muscle explants, suggesting that 
MGF is particularly active in muscle cells, and that it still has activity even in diseased muscle 
(6). 
 Studies have also been conducted with MGF in non-muscle tissues and cells. Looking at 
brain ischemia, synMGF has neuroprotective activity and prevents cell death in oxidatively 
stressed hippocampal cultures (27). So, in addition to promoting growth at the expense of 
differentiation, MGF has protective activity. This is interesting, as IGF-I is antiapoptotic (57). In 
the heart, MGF expression increases after cardio infarction, and synMGF increases myocyte 
proliferation (98). Unfortunately, this increase in proliferation and prevention of cell death can 
have detrimental effects, as MGF is highly expressed in prostate cancer (5), and synMGF 
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increases growth in osteosarcoma cells (76). While MGF may be a potent growth factor in 
muscle, its properties are not unique to skeletal muscle, as its pro-growth actions are observed in 
other cell and tissue types.  
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Figure 1-5 
 
 
 
 
Figure 1-5. MGF/IB is expressed quickly after injury and overload, and IA is expressed 
later, leading to the “MGF Hypothesis.” A-B. Expression pattern of MGF/IB (A) and IA (B) 
after an Eccentric Contraction (ECC) which injures muscle. Open bars represent injured muscles; 
gray bars are uninjured contralateral controls. This data led to the “MGF Hypothesis” C. The 
MGF Hypothesis. MGF/IB peaks in expression before satellite cell activation, and IA peaks later. 
So, the E-peptide B (Eb) from MGF/IB activates satellite cells but declines in expression before 
differentiation occurs. IA expression (including E-peptide A, Ea) increases, providing the IGF-I 
necessary to promote differentiation. A and B adapted from (46), and C adapted from (65). 
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E-peptide Controversy  
 It is curious that so much work has focused on the activity of MGF/EB/hEC while only a 
few experiments have explored the activity of the novel human EB, and no studies have focused 
on EA. The only study that even addressed EA only included it in one experiment. In this study, 
recombinant human EA did not have as much activity as human EB at reducing cancer colony 
formation, and so they focused on human EB for the remaining experiments in the study (54). In 
some ways, it makes the most sense for EA to have a biological function, as it more highly 
expressed than the other isoforms (61), and because the region of DNA that codes for the EA 
peptide is more highly conserved than the regions coding for the other E-peptides. The sequence 
conservation in this region suggests that this peptide has biological activity in many species 
(105). Instead, the field has focused on the activity of the stretch- and injury-inducible 
MGF/IB/hIC isoform. 
 While many studies have proposed, tested, and concluded that MGF is a potent regulator 
of muscle growth that activates satellite cells, these studies have been met with criticism. The 
skepticism has been fueled by the Goldspink group and conclusions made about MGF that had 
little or no experimental evidence. As an example, in Goldspink’s first review after naming MGF, 
he claims that MGF controls local tissue repair, maintaince, and remodeling and that this igf1 
isoform is designed for autocrine function. These conclusions were made when the only 
published data about MGF showed that its expression increases with stretch. His conclusions 
were somewhat premature, as MGF being an exclusive local autocrine factor is not supported by 
any data, even 13 years later. Specifically, MGF/IB is expressed more in the liver, (13% of all 
igf1 transcripts) than in muscle (2.5%) (61). Also, IB expression is more sensitive to GH than IA, 
which suggests an endocrine function for MGF/IB. 
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 One major concern for the MGF literature is that many conclusions about MGF activity 
were based on unpublished data. In several review articles (36, 37, 39, 41), Goldspink cites data 
from meeting abstracts, patents, and unpublished experiments. In one review (39), Goldspink says 
that his lab made GFP-MGF and GFP- IA fusion constructs and transfected them into cells. While 
IA stayed in the cytoplasm, MGF localized to the nucleus. These data would be very useful to the 
IGF-I field, as it would show a biological reason for splicing to IA vs IB/IC: that the E-peptides 
can localize IGF-I to different sub-cellular compartments. But as these experiments have never 
been published in a peer-reviewed article, they cannot be considered credible findings.  
 Another example concerns a novel finding that MGF overexpression causes hypertrophy. 
Goldspink describes an experiment in which a plasmid containing MGF cDNA was injected into 
mouse muscle (39). After 3 weeks, the injected muscle mass was 20% larger than control muscle, 
and the average fiber size went up 25%. From these results, Goldspink concludes that MGF is a 
potent muscle growth factor, and that it causes hypertrophy more quickly than IA. When 
explaining these findings, Goldspink cites his 1997 patent (40) that describes the exon 4-5-6 
isoform that is later named MGF. Shockingly, this patent does not contain the plasmid injection 
experiment. There is no mention of mouse muscle, hypertrophy, or plasmid injection, even 
though other experiments and results are outlined. So, a large conclusion about MGF and 
hypertrophy is based on an untraceable experiment. 
 In addition to unpublished data, the terminology that the Goldspink introduced into the 
already confusing igf1 “A, B, C” terminology caused misunderstanding. Many researchers 
believed that MGF was truly muscle-specific and that the resulting IGF-I was somehow different 
than IGF-I made in the liver. This is not true, as the resulting IGF-I from all isoforms is exactly 
the same, and MGF/IB/hIC is expressed in the liver (61). Additionally, it is often unclear as to 
whether the “MGF” studied refers to full-length MGF (pro-IB/hIC), the E-peptide of MGF 
22 
 
cleaved away from the mature IGF-I protein (EB/hEC), or the 24/25-mer peptide corresponding 
to the amino acids from exon 5 and 6 (synMGF). 
 Further, the MGF hypothesis is somewhat misleading. While it is true that the expression 
of MGF/IB/hIC increases after injury or overload, its expression never reaches the levels of IA 
(44, 46, 65, 74). Consequently, the concentration of EA is always higher than MGF/EB/hEC. 
Also, MGF/IB expression delays differentiation in C2C12 myoblasts (110), and the expression of 
MGF/IB/hIC falls before myoblast fusion occurs after injury, implying that reducing MGF should 
increase differentiation. This is not the case, however, as knocking-down IB in C2C12 myoblasts 
delays differentiation (64). Alternatively, increased MGF should delay differentiation, but MGF 
enhances differentiation of human muscle cell cultures (52). 
 These examples and others created skepticism in the field. Are any MGF findings real? 
Have MGF effects been blown out of proportion? Is MGF truly a potent, muscle-specific growth-
promoter and satellite cell activator? Is MGF activity actually due to the residues from exons 5 
and 6, or simply due to the IGF-I made from the MGF/IB isoform? The criticisms, skepticisms, 
and questions on the topic of MGF has led to a call for more thorough experiments to be 
conducted to determine the biological relevance of MGF/IB (65). 
 
Comparing the full length rodent isoforms 
 Our group has set out to determine how the E-peptides affect IGF-I activity, and which 
rodent igf1 isoform is the most potent at promoting growth and inducing hypertrophy in muscle. 
We expressed IA and IB in mouse hindlimbs via Adeno-associated virus vectors (AAV). Both 
isoforms caused an equilvelant amount of hypertrophy in young mice, but only IA caused 
hypertrophy in aged mice (9). The results from this direct comparison of the IGF-I isoforms 
suggest that they have both unique and common properties. While the results dispelled the myth 
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that MGF/IB is more potent than IA, they also showed that IB is not as functional in aged muscle, 
suggesting that EA and EB act differently in vivo. Since one of the main differences between 
young growing muscle and mature muscle is the presence and absence of activated satellite cells, 
respectfully, it is possible that IB requires an activated satellite cell pool to cause hypertrophy, 
while IA does not. Perhaps the E-peptide modulates how IGF-I can activate receptors on the 
surface of myofibers or satellite cells. Interestingly both IA and IB caused more hypertrophy 
when compared to expressing a mature IGF-I only (no E-peptide), implying that the E-peptide is 
necessary and important for proper IGF-I secretion, IGF-IR activation, and downstream signaling 
(10). 
 To look specifically at secretion, internalization, and localization of IGF-I and the E-
peptides, we expressed fluorescently-tagged constructs in myoblast cell culture (75). We found 
that the presence of either E-peptide enhanced the internalization of IGF-I, showing that they 
share common properties in modulating IGF-I. We also found that mature IGF-I (no E-peptide), 
pro-IA, pro-IB, EA and EB are secreted from myoblasts, so the E-peptide is not necessary for 
IGF-I secretion. Not only were the free E-peptides secreted, but they were then internalized into 
other cells. This study showed no difference between EA and EB, but it did show that the E-
peptides modulate IGF-I secretion, and this activity could lead to IA and IB inducing more 
hypertrophy than mature IGF-I alone. 
 
E-peptide activity: dependent or independent of IGF-I? 
 Goldspink suggested that MGF/EB may be involved in IGF-I secretion or the binding of 
IGF-I to its receptor (40), and very early on it was proposed that the E-peptides could affect IGF-
IR binding, binding partners binding, or that the E-peptides could have distinct roles by 
themselves (61). However, since the igf1 gene encodes one E-peptide for every mature IGF-I, and 
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that most of the published functions of the E-peptides are similar to IGF-I actions, it is difficult to 
discriminate IGF-I and E-peptide effects. The E-peptides may have independent activity, or they 
could simply modulate IGF-I expression, secretion, stability, or signaling via IGF-IR.  
 Many studies have attempted to prove E-peptide independent activity by blocking the 
IGF-I signaling. In the presence of IGF-IR neutralizing antibodies, human EB increases the 
proliferation of epithelial cells (95) and synMGF can increase proliferation of C2C12 myoblasts 
(78, 110), myogenic precursor cells (70), and rat cardiomyocytes (98), and increases human 
myogenic cell migration (71) and the proportion of human myogenic cells (6). Additionally, 
synMGF increases growth in osteosarcoma cells even when IGF-IR is not expressed (76). These 
results suggest that the E-peptides have activity independent of IGF-IR signaling. 
 There is also evidence that the E-peptides modulate IGF-I signaling and uptake (9, 75), so 
it is still unclear whether the E-peptides affect IGF-I and IGF-I signaling. Also, synMGF and hEB 
increase ERK 1/2 phosphorylation (54, 78, 98), and hEB affects neurite outgrowth in an MAPK 
and PI-3K dependent manner. These pathways are downstream of IGF-IR, thus potentially 
linking E-peptides and IGF-IR activation. In addition, synMGF can increase the proliferation of 
human muscle cells, while also increasing their fusion and causing myotubes hypertrophy. Its 
ability to enhance both proliferation and differentiation resembles that of IGF-I itself (52). 
Further, it is completely unknown if EA has any activity besides increasing IGF-I secretion, and 
if it does, whether its activity is IGF-IR independent. 
 
Purpose of my thesis 
 The goals of my thesis are to determine the activity of the two rodent E-peptides, EA and 
EB, in skeletal muscle growth. The study will compare EA and EB in myoblast signaling, 
proliferation, differentiation, and their ability to cause hypertrophy and activate satellite cells in 
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vivo. Moreover, I aim to determine if the E-peptides actions are truly IGF-I and IGF-I signaling 
independent. Focus will be placed on confirming the proposed actions of MGF/EB while 
comparing EB activity to that of EA, which has never been studied in skeletal muscle.  
 Since so many of the proposed activities of the E-peptides are similar to the actions of 
IGF-I, and E-peptide effects could be attributed to IGF-I modulation and not specifically to the 
independent actions of the E-peptides, it is difficult to focus on the actions of the E-peptides 
alone. Simply expressing the two igf1 isoforms, IA and IB, would also increase the expression of 
IGF-I, and the effects of E-peptide expression may be clouded by IGF-I activity. To study E-
peptide actions alone, the E-peptide must be presented or expressed without also increasing IGF-
I. I will accomplish this in two ways: First, by the exogenous addition of synthetic E-peptides to 
myoblasts in cell culture, and second, by expressing mutated IA and IB in vivo, where IGF-I is 
non-functional, but EA and EB are unaffected 
 In Chapter II I will describe the results of the exogenous addition of synthetic E-peptides 
in myoblast cell culture. In these experiments, I also used an inhibitor of IGF-IR phosphorylation 
to further tease apart E-peptide and IGF-I signaling. I found that both E-peptides increase 
ERK1/2 phosphorylation, and that this result depends on a functional IGF-IR. Next, I specifically 
looked at IGF-IR activation and localization, and found that the E-peptides augment IGF-IR 
signaling in part by affecting IGF-IR availability on the cell surface. Finally, I compared the E-
peptide affects on muscle growth using a myoblast cell culture model. EB increased myoblast 
proliferation and migration in an IGF-IR dependent manner, and EA delayed differentiation. So, 
both E-peptides have common and unique activity in muscle cells, but most of the activity is IGF-
IR dependent. 
 In Chapter III, I will present evidence that EB can cause hypertrophy in vivo, and that this 
activity is likely dependent on IGF-IR. To study the expression of EA and EB in vivo, I expressed 
mutated IA and IB in mouse hindlimb muscles using Adeno-associated viral (AAV) vectors. The 
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mutation rendered the IGF-I non-functional, but the E-peptides were unaffected. In this way, the 
E-peptides are processed normally, but there is no increase in functional IGF-I. Both E-peptides 
increased ERK1/2 phosphorylation, as they do in cell culture. EB expression led to an increase in 
muscle mass and fiber area, but there was no hypertrophy in mice lacking functional IGF-IR. 
Also, mice expressing EB for a long period of time developed weaker muscles, and both E-
peptides caused a decrease in satellite cells. I conclude that both rodent E-peptides have activity 
in muscle, that EB is more potent at promoting growth, but that most of the E-peptide activities 
rely on IGF-IR signaling. My results suggest that E-peptides do not have much independent 
activity; instead they modulate IGF-I signaling, and are a method through which nature increases 
IGF-I activity regulation. 
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Abstract 
 Insulin-like growth factor-I (IGF-I) is an essential growth factor that regulates the 
processes necessary for cell proliferation, differentiation, and survival. The igf1 gene encodes 
mature IGF-I and a carboxy-terminal extension called the E-peptide. In rodents, alternative 
splicing and post-translational processing produce two E-peptides (EA and EB). EB has been 
studied extensively and has been reported to promote cell proliferation and migration 
independently of IGF-I and its receptor (IGF-IR), but the mechanism by which EB causes these 
actions has not been identified. Further, the properties of EA have not been evaluated. Therefore, 
the goals of this study were to determine if EA and EB possessed similar activity and if these 
actions were IGF-IR independent. We utilized synthetic peptides for EA, EB, and a scrambled 
control to examine cellular responses. Both E-peptides increased MAPK signaling, which was 
blocked by pharmacologic IGF-IR inhibition. Although the E-peptides did not directly induce 
IGF-IR phosphorylation, the presence of either E-peptide increased IGF-IR activation by IGF-I, 
and this was achieved through enhanced cell surface bioavailability of the receptor. To determine 
if E-peptide biological actions required the IGF-IR, we took advantage of the murine C2C12 cell 
line as a platform to examine the key steps of skeletal muscle proliferation, migration and 
differentiation. EB increased myoblast proliferation and migration while EA delayed 
differentiation. The proliferation and migration effects were inhibited by MAPK or IGF-IR 
signaling blockade. Thus, in contrast to previous studies, we find that E-peptide signaling, 
mitogenic, and motogenic effects are dependent upon IGF-IR. We propose that the E-peptides 
have little independent activity, but instead affect growth via modulating IGF-I signaling, thereby 
increasing the complexity of IGF-I biological activity. 
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Introduction 
 Insulin-like growth factor-I (IGF-I) is a circulating autocrine/paracrine factor that 
regulates pre- and postnatal growth in many tissues. Proper embryonic development relies on 
IGF-I signaling, as IGF-I Receptor (IGF-IR) knockout mice die at birth, and IGF-I knockout mice 
rarely survive (38). The IGF-I null mice that do survive have diminished organismal growth (4), 
whereas mice over-expressing IGF-I systemically are 1.3 times as large as controls (44), 
indicating that IGF-I signaling is also essential for normal postnatal growth.  
  IGF-I is one of the major growth factors that directs skeletal muscle development, 
growth, and regeneration. When IGF-IR is specifically inactivated in skeletal muscle, muscles are 
10-30% smaller (25, 46). Increasing IGF-I in muscle by infusion of recombinant IGF-I (2), 
transgenic over-expression (15, 50), or viral gene delivery (9), causes hypertrophy, can improve 
diseased muscle phenotype and function (8, 41), and enhances regeneration after injury (57, 60).  
 IGF-I activates the conventional pathways of muscle cell proliferation and differentiation 
in growth and repair (56). Muscle regeneration relies on a stem cell-like niche of quiescent 
muscle progenitor cells called satellite cells. Once activated, the satellite cells become myoblasts, 
proliferate, migrate to the region of injury, and differentiate by fusing with myofibers (reviewed 
in (26)). IGF-I is upregulated in hypertrophic muscles and after damage or overload (1, 32), and 
stimulates satellite cells (10). IGF-I regulates muscle growth via binding to and activating IGF-
IR. Upon IGF-I binding, IGF-IR is autophosphorlated at several sites on its cytoplasmic tails, 
which initiates multiple signaling cascades. Activated IGF-IR triggers the MAPK pathway, 
increasing proliferation and migration in satellite cells and myoblasts. The PI3-Kinase/Akt 
pathway is also stimulated, which leads to increased differentiation and protein synthesis in 
mature muscle fibers (18, 33, 37).   
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 The general consensus is that these growth effects are mediated by mature IGF-I, but the 
igf1 gene encodes more than just the mature growth factor. igf1 pre-mRNA is alternatively 
spliced at the 5’ and 3’ ends, generating multiple isoforms. The igf1 gene and its splicing are 
highly conserved in vertebrates (64). The pre-proproteins consist of the signal peptide, IGF-I, and 
a carboxy-terminal extension called the E-peptide (59). In rodents, there are 2 possible E-peptide 
extensions: EA and EB. In humans, 3 possible E-peptide extensions have been identified: EA, EB 
(unique) and EC (like rodent EB) (70). In all cases, the predominant igf1 isoform expressed is 
igf1a, which is the most conserved across all species examined (39, 40, 63, 64, 70). Subtilisin-
related proprotein convertases (SPCs) can cleave proIGF-I within the constitutive secretory 
pathway, resulting in mature IGF-I and any of the E-peptides (22-24). In addition, IGF-I still 
connected to the E-peptides (pro-IGF-I) has been found outside of cells, implying that not all of 
the IGF-I produced is secreted in the mature form, and that the E-peptides can be secreted out of 
the cell still attached to IGF-I (16, 17, 71). All isoforms encode the identical mature IGF-I 
protein, but the E-peptides share less than 50% amino acid identity (5). For clarity, we will use 
the rodent terminology, as this study focuses on the rodent isoforms. 
 The functions of the E-peptides are largely unknown, but focus has been on the less 
prominent isoforms rather than EA. Much attention has been paid to EB particularly in muscle, 
where this form has been deemed “Mechano Growth Factor” (MGF) due to rapid transcriptional 
upregulation of igf1b after stretch, overload, and injury (29, 47, 74, 75). Exposure to MGF/EB 
peptides has been shown to increase myoblast proliferation and migration, and overexpression of 
igf1b delays differentiation (48, 49, 76). Many of these effects were apparent even when IGF-IR 
was blocked via a neutralizing antibody, indicating that EB-peptide actions were independent of 
IGF-I signaling. While MGF/EB has been extensively investigated in muscle growth, EA has 
been all but ignored, even though 90-95% of the mammalian igf1 mRNA transcripts are igf1a 
(39).  
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 Comparisons of the IGF-I isoforms support that they have both unique and common 
properties. Increased expression of igf1a and igf1b causes different degrees of hypertrophy in 
adult mice (6), suggesting that EA and EB act differently in vivo. In addition, the presence of 
either E-peptide enhances the entry of IGF-I into cells (52), showing that they may also share 
common properties in modulating IGF-I. However, since the igf1 gene encodes one E-peptide for 
every mature IGF-I, and that most of the published functions of the E-peptides are similar to IGF-
I actions, it is difficult to discriminate IGF-I and E-peptide effects. In this study, we have utilized 
synthetic E-peptides to manipulate E-peptide levels independently of IGF-I. The goals of this 
study are to determine if the E-peptides act independently of IGF-I and IGF-I signaling, and to 
compare EA and EB biological actions in the model of muscle formation, which includes 
signaling, proliferation, migration, and differentiation.  
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Results 
EA and EB synthetic E-peptides enhance MAPK Signaling 
 IGF-I is known to activate the MAPK and PI3-Kinase/Akt pathways in many cell types 
including skeletal muscle myoblasts (45, 56, 57). If the E-peptides work similarly to, or in concert 
with IGF-I, they may also affect these signaling pathways. Indeed, previous studies have 
examined the effects of the E-peptides in the MAPK signaling cascade and have observed that 
synthetic MGF peptide increased ERK phosphorylation in rat cardiomyoblasts (66), and in mouse 
skeletal muscle myoblasts (53). However, EA has never been evaluated for signaling effects. To 
compare EA and EB in C2C12 mouse myoblast culture, synthetic E-peptides were generated 
(Figure 2-1). The synthetic peptides begin immediately following the SPC site in exon 4. They 
include the C-terminal portion of exon 4, plus exon 6 (EA) or exons 5 and 6 (EB) (Figure 2-1 A). 
In contrast to the MGF peptide used in previous studies, which included only the unique portion 
encoded by exons 5 and 6, the more biologically relevant EB peptide we generated includes 
additional residues that would be retained following cleavage of pro-IGF-I. A scrambled (Scr) 
peptide was also generated as a negative control. 
 To compare E-peptide effects on signaling, C2C12 cells were exposed to synthetic E-
peptides. Multiple signaling pathways were initially examined (SMAD, p38, Jnk, and Akt), but 
only the MAPK pathway was affected by E-peptide exposure. To determine the response to E-
peptides, immunoblotting for phosphorylated and total ERK1/2 was performed following 
treatment with increasing concentrations of EA, EB, or Scr (Figure 2-2 A-C). Increased ERK1/2 
phosphorylation was evident with E-peptide concentrations as low as 1nM. EA exhibited dose-
dependent signaling. EB was more potent, with significantly higher P-ERK1 at 1nM compared to 
untreated cells (NoTx, DMEM without serum, IGF-I, or E-peptides). The maximum response to 
EB occurred at 10nM, with diminished phosphorylation at higher concentrations (100nM-1µM). 
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ERK1 had higher activation than ERK2 at optimum dose for both EA and EB, with 8 times more 
phosphorylation than NoTx for ERK1, and 3 times more for ERK2. Scr did not increase P-ERK 
1/2 significantly at any concentration, and thus the P-ERK1/2 responses were specific to each 
sequence, and not to a random peptide. 
 Next, the synthetic E-peptides were used at concentrations generating the optimum 
response (EA and Scr 1µM, EB 10nM) to examine the time course of ERK1/2 phosphorylation 
(Figure 2-2 D-F). Cells treated with DMEM only (NoTx) were also collected at times indicated to 
obtain the time-course baseline of ERK1/2 phosphorylation. EA treatment showed an increase in 
P-ERK1/2 early (5 min), but because NoTx cells had a high basal ERK1/2 phosphorylation at 5 
minutes, the difference was not significant after quantification. Both E-peptides generated a 
transient increase in P-ERK1/2. EA-induced P-ERK1/2 reached maximum levels by 15 minutes 
after E-peptide addition, but fell to untreated levels by 30 minutes. In contrast, the P-ERK1/2 
response to EB was not detectable until 15 minutes after exposure, but remained elevated for at 
least 30 minutes. Exposure to Scr did not cause any increase in P-ERK1/2 at any time point. 
Thus, both E-peptides can transiently increase ERK1/2 phosphorylation at their optimum 
concentrations; however, EB is active at lower concentrations for a more sustained period.  
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Figure 2-1 
 
 
Figure 2-1. Synthetic E-peptide sequences. A. Rodent igf1 3’ splicing leads to two mRNA 
isoforms. While mature IGF-I is encoded by exons 3 and 4, the E-peptides are encoded by exons 
4, 5, and/or 6. EA isoforms exclude exon 5, while EB isoforms retain exon 5, leading to an 
altered reading frame and earlier stop codon in exon 6. Exons not drawn to scale B. Synthetic E-
peptide amino acid sequences. EA and EB are less than 50% identical. Scr = Scrambled peptide. 
* = potential glycosylation sites in EA. The portion of EB that corresponds to MGF is underlined.  
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Figure 2-2 
 
 
 
Figure 2-2. EA and EB increase MAPK signaling in C2C12 cells. A. Cells were starved in 
media without serum, and treated with synthetic E-peptides at concentrations indicated for 20 
minutes. Protein lysates were separated via SDS-PAGE and immunoblotted for Phosphorylated 
ERK 1 and 2 (P-ERK1/2), stripped, and blotted for Total ERK 1 and 2 (T-ERK1/2). B-C. 
Quantification of A. D. Cells were treated as above at optimal doses (EA and Scr 1µM, EB 
10nM) for times indicated. E-F Quantification of C. NoTx at 30 minutes was included in each 
experiment for normalization between blots. For B-C and E-F, bars represent means ± s.e.m. of 
N=3 replicates. *, p<0.05; ***, p<0.001, for comparisons to NoTx via 2-way ANOVA followed 
by a Bonferroni post-test.   
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E-peptide signaling depends on the IGF-I Receptor 
 Although IGF-I and the E-peptides are produced by the same gene, there is no known 
functional relationship between them; however, because they share the ERK1/2 phosphorylation 
response, it is possible that the E-peptides enhance MAPK signaling cooperatively with IGF-I via 
the IGF-IR. To determine if the E-peptide signaling effects were dependent upon IGF-I signaling, 
pharmacologic inhibition of the IGF-IR was utilized in conjunction with E-peptide exposure. 
NVPAEW541 (NVP), a small molecule inhibitor of IGF-IR tyrosine kinase activity (27), was 
utilized in combination with IGF-I or the E-peptides. Treatment with IGF-I caused an increase in 
both P-Akt and P-ERK1/2, and these responses were blocked in the presence of NVP (Figure 2-3 
A,B) confirming that NVP effectively inhibited IGF-IR signaling. Using the E-peptide 
concentrations shown in Figure 2-2, both EA and EB caused increased P-ERK1/2, but no change 
in P-Akt (Figure 2-3 A, lanes 1-3). Interestingly, in the presence of NVP, the P-ERK1/2 response 
was ablated in EA and EB treated cells to a similar extent as in IGF-I treated cells (Figure 2-3 B). 
There was no change in ERK1/2 phosphorylation in NoTx cells with or without NVP, which 
verified that NVP did not affect IGF-I-independent MAPK signaling. However, NVP 
significantly reduced the ERK1/2 phosphorylation in EA, EB, and IGF-I treated cells, 
establishing that a functional IGF-IR is required for E-peptide induced ERK1/2 activation.  
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Figure 2-3 
 
 
 
Figure 2-3. E-peptide ERK signaling requires IGF-IR. A. C2C12 cells were treated as in 
Figure 2, except the IGF-IR inhibitor NVPAEW541 (NVP, 100nM) or DMSO was added to cells 
90 minutes prior to and during stimulation for 20 minutes. Cells were treated with EA (1µM), EB 
(10nM), or recombinant IGF-I (IGF, 10nM) as a positive control. EA and EB experiments were 
conducted separately, and image represents one sample from each experiment. B. Quantification 
of A. Data are presented as the effect of NVP on ERK phosphorylation: (P/T-ERK of NVP 
treated)/(P/T-ERK of DMSO treated cells). NoTx bands were used to compare between 
experiments. Bars represent means ± s.e.m. of N=3 replicates. *, p<0.05 for comparisons of 
treatments to NoTx via 1-way ANOVA followed by a Tukey post-hoc test; †, p<0.05 for 
comparisons of NVP samples to their DMSO counterparts via student t-tests.    
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E-peptides enhance IGF-IR activation by IGF-I through increasing receptor cell surface 
bioavailability 
 The IGF-IR dependence of E-peptide signaling could be due to direct interaction of the 
E-peptides with the receptor, or through an indirect mechanism with the IGF-I ligand. To test 
IGF-I dependent and independent IGF-IR activation by the E-peptides, a kinase receptor 
activation (KIRA) assay was performed. This assay utilizes IGF-IR over-expressing mouse 
fibroblasts (P6 cells) (19, 55) to provide sufficient receptor density for detection. IGF-I alone 
stimulated IGF-IR phosphorylation dramatically and significantly at 2nM and 10nM. In the 
absence of IGF-I, cells treated with EA, EB, or Scr showed no evidence of receptor activation 
(Figure 2-4 A,B). However, combined exposure of IGF-I and either EA or EB significantly 
increased IGF-IR activation compared to IGF-I alone. EA at 10 and 100 nM significantly 
increased IGF-IR activation compared to no peptide in the presence of 2 or 10 nM IGF-I. EB was 
less potent, significantly increasing IGF-IR phosphorylation at 100 nM with IGF-I at 2 and 10 
nM. Scr at 100 nM was used as a negative control, and it did not increase IGF-IR phosphorylation 
at any concentration of IGF-I. These results indicate that although the E-peptides do not activate 
IGF-IR directly, they augment IGF-IR activation in an IGF-I-dependent manner. 
 The lack of direct E-peptide activation of IGF-IR in combination with enhancement of 
ligand-mediated activation suggests that the E-peptides could modulate the availability of 
receptors for IGF-I. To examine this, cell-surface proteins on P6 cells were biotin labeled after 
treatment with the E-peptides and/or IGF-I for 15, 30, and 60 minutes, and cell-surface IGF-IR 
was compared to total IGF-IR. Overall, IGF-I and NoTx showed the same pattern of 
internalization from 0-30 minutes, with an accumulation of recycled cell surface receptors (69) in 
IGF-I treated cells by 60 minutes. However after 15 minutes, the time point used in the KIRA 
assay, stimulation with IGF-I and either E-peptide caused a significant increase in the proportion 
of IGF-IR on the cell surface compared to NoTx and IGF-I alone (Figure 2-4 C). Thus, one 
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mechanism for augmented IGF-IR activation after E-peptide stimulation is that the E-peptides 
increase the bioavailability of IGF-IR for its ligand, IGF-I, by increasing cell surface IGF-IR. 
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Figure 2-4 
 
 
Figure 2-4. E-peptides augment IGF-IR activation and cell surface localization. A. P6 cells 
overexpressing IGF-IR were treated with synthetic E-peptides with and without recombinant 
IGF-I for 15 minutes, and cell lysates were utilized for KIRA assays. Level of absorbance 
indicates the extent of IGF-IR phosphorylation. Bars represent means ± s.e.m. of N=6 wells. B. 
OD 450 from A were compared to No Peptide for each IGF-I concentration, and the % change is 
graphed. C. P6 cells were treated as in A for a localization assay for times indicated, and biotin 
labeled before lysis. The optimal concentrations of E-peptides and IGF-I from the A were used 
(E-peptides 100nM, IGF-I 10nM). Surface IGF-IR was normalized to Total IGF-IR and compared 
to NoTx at t0 to get % IGF-IR on cell surface. Bars represent means ± s.e.m. of N=6 wells. 
Samples were compared to no peptide (A and B,*), NoTx (C,*) or IGF-I (C,†) via 2-way 
ANOVA followed by a Bonferroni post-test. * or †, p<0.05; ***, p<0.001.  
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E-peptides enhance IGF-IR downstream signaling 
 Since we observed that the E-peptides augment IGF-IR signaling in P6 cells (Figure 2-4), 
and increase MAPK signaling but not Akt phosphorylation in myoblasts (Figure 2-2), we 
predicted that the E-peptides might differentially activate a subset of IGF-IR mediated pathways. 
To test if the E-peptides could alter MAPK or Akt/PI3Kinase pathways after IGF-I stimulation in 
myoblasts, C2C12 cells were stimulated with the E-peptides alone, IGF-I alone, or IGF-I plus EA 
or EB. Consistent with our previous signaling experiments, without IGF, the E peptides increased 
P-ERK1/2 approximately 2-4 fold compared to NoTx (0nM IGF-I), and there was no change in P-
Akt. In the presence of 2 nM IGF-I, there was also a 2-4 fold increase in P-ERK1/2 with the 
addition of the E peptides compared to IGF-I alone (Figure 2-5 A-C). The E-peptide enhancement 
of IGF-IR phosphorylation may have led to altered IGF-IR downstream signaling, which favored 
MAPK without altering Akt/PI3Kinase pathways. In addition, the enhancement in P-ERK2 after 
IGF-I and EA treatment compared to IGF-I alone was significantly higher than the enhancement 
after EA vs NoTx, indicating that EA may augment IGF-I potency. 
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Figure 2-5 
 
 
 
Figure 2-5. E-peptides affect IGF-IR downstream signaling. A-C. C2C12 cells were treated as 
in Figure 2, with 0nM or 2nM IGF-I and optimal doses of the E-peptides (EA 1µM, EB 10nM) 
for 20 minutes. B-C. Quantification of Akt and ERK1/2 phosphorylation after EA (B) or EB (C) 
treatment. EA and EB alone are compared to NoTx, while IGF-I with E-peptides are compared to 
2nM IGF-I alone. Data are presented as the effect on phosphorylation after E-peptide treatment 
compared to NoTx or NoPeptide plus IGF-I. Bars represent means ± s.e.m. of N=3-4 replicates. 
†, p<0.05 for comparisons of 0nM IGF samples to their 2nM IGF-I counterparts via student t-
tests.  
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 E-peptide effects on myoblast proliferation and migration are IGF-IR dependent 
 To examine the importance of IGF-IR for the biological actions of the E-peptides, we 
utilized the model of skeletal muscle growth in cell culture, which has been studied extensively 
with IGF-I and MGF (42, 51, 76). First, we focused on myoblast proliferation, which increases in 
the presence of IGF-I (56) and MGF/EB (14, 35, 49, 65, 67, 76), but neither EA nor full-length 
EB have been evaluated in myoblasts. Therefore, we determined the effects of EA, EB, and Scr 
on myoblast proliferation. We examined C2C12 proliferation in an ELISA plate assay for BrdU 
after treatment with the synthetic E-peptides at different concentrations. While both EA and EB 
treated cells showed a modest trend towards increased proliferation at all concentrations, only 10 
and 100 nM EB increased proliferation significantly, by approximately 35-40% (Figure 2-6 A). 
To directly observe the proliferating cells, C2C12 cells were grown on cover slips and examined 
for BrdU positivity using fluorescent microscopy. Recombinant IGF-I treatment was used as a 
positive control. EB and IGF-I increased C2C12 proliferation, but EA did not (Figure 2-6 B).  
 To clarify if the proliferative effects of EB were mediated by the MAPK pathway or 
dependent upon IGF-IR, cells were exposed to the optimum concentration of EB (10nM), with or 
without pharmacologic inhibition of MEK, a MAP kinase upstream of ERK, by PD 098059 (PD) 
(21), or by NVP to inhibit IGF-IR activity (Figure 2-6 C). IGF-I (10nM) was used as a positive 
control. PD and NVP significantly decreased IGF-I induced proliferation, confirming that IGF-I 
mediates these effects predominantly through the MAPK pathway and IGF-IR. EB increased 
proliferation significantly without inhibitors, but these effects were blocked in the presence of PD 
or NVP. Therefore, EB requires MAPK signaling and a functional IGF-IR to increase myoblast 
proliferation.  
 In skeletal muscle growth and repair, after myoblasts proliferate, they must migrate to the 
areas in need of extra nuclei. Myoblast migration has been linked to MAPK signaling activation 
(36). Accordingly, the increase in ERK1/2 phosphorylation after E-peptide stimulation could lead 
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to increased myoblast migration. To determine if the E-peptides modulate migration, and if the 
effects are MAPK or IGF-IR dependent, a trans-well assay using serum-starved C2C12 cells was 
used (Figure 2-6 D). Only EB treatment caused enhanced myoblast migration, with a 70% 
increase in the number of migrating cells, whereas EA treated cells showed ~30% enhancement 
that was not significantly different from untreated cells. Cell migration in the absence of E-
peptides was not affected by either PD or NVP, most likely due to the brief duration of the 
experiment in the absence of serum, and thus an absence of endogenously secreted growth 
factors. Blockade of MAPK signaling by PD caused a decrease in EB migration that did not reach 
significance, suggesting that EB mediates migration via pathways in addition to MAPK. 
Blockade of IGF-IR activation by NVP significantly decreased EB induced migration, indicating 
that EB requires IGF-IR to increase myoblast migration. Interestingly, with EA, there was not a 
significant increase in migration without inhibitors, yet both inhibitors decreased migration 
significantly when EA was present. In sum, migration driven by the E-peptides, especially EB, is 
dependent upon the IGF-IR. 
  
  
52 
 
Figure 2-6 
 
 
 
Figure 2-6. EB increases in myoblast proliferation and migration are MAPK and IGF-IR 
signaling dependent. A. C2C12 cells were plated in 96 well plates, starved for 6 hours, and 
treated with synthetic E-peptides. A BrdU plate assay was used to quantify proliferating cells, 
where increased absorbance is correlated with increased proliferation. Bars represent means ± 
s.e.m. of N=10 wells. B. A similar BrdU assay was used to visualize the proliferating cells on 
slides. Cells were treated as above (EA and Scr 100nM, EB and IGF 10nM), fixed, and stained 
with BrdU and DAPI. Total cells and proliferating (BrdU positive) cells were counted from 3 
10X fields for each slide, and bars represent means ± s.e.m. of N=5 slides. For A and B, * , 
p<0.05; ***, p<0.001 for comparisons to NoTx via 1-way ANOVA followed by a Tukey post-
hoc test. C. C2C12 cells were tested as in A, except an inhibitor of MEK, PD 098059 (PD, 50 
µM) or IGF-IR (NVP, 100nM) was included in the cell media. Bars represent means ± s.e.m. of 
N=18 wells for No Inhibitor (No Inh) and N=8 for with inhibitors. D. C2C12 cells were plated in 
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the upper chamber of 24-well plate trans-well migration inserts in 0% serum media. Cells were 
allowed to migrate for 5 hours and stained with DAPI, imaged and counted. Synthetic E-peptides 
(100nM) were added to upper and lower chambers with or without inhibitors (PD 50µM, NVP 
100nM). Images were taken as in B, and bars represent means ± s.e.m. of N=4 slides. For C and 
D, * , p<0.05; ***, p<0.001 for comparisons to NoTx via 2-way ANOVA followed by a 
Bonferroni post-test. † , p<0.05 for comparisons to No Inh via 2-way ANOVA followed by a 
Bonferroni post-test. 
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Myoblast differentiation is inhibited by E-peptides  
 Skeletal muscle growth and repair rely on satellite cells and myoblasts to fuse with 
existing muscle fibers or with each other to differentiate into new muscle fibers. This process can 
be replicated in culture to examine key markers of differentiation and myotube formation. 
Previous studies showed that MGF/IGF-IB delays myoblast differentiation (76). To compare the 
effects of EA and EB on differentiation, we treated differentiating C2C12 cells with EA, EB, or 
Scr synthetic peptides for three days and used qRT-PCR to evaluate changes in expression of 
differentiation markers MyoD (Myod), Myogenin (Myog), and Embryonic myosin (Myh3) (Figure 
2-7 A-C). All three markers increased as days of differentiation increased. There was no 
significant difference between treated cells at any day for Myod or Myog, however, there was 
significantly less Myh3 expression in EA treated cells versus Scr treated cells at both Day 2 and 3. 
EB treated cells showed a trend towards lower Myh3 expression, but it did not reach significance. 
Thus EA impaired the later stages of differentiation and maturation. 
 In this study, EB did not inhibit differentiation, although MGF has been shown to delay 
differentiation (76). This may be because EB, which has a potential protease cleavage site, is not 
stable in cell media for long enough to consistently affect differentiation. To determine the half-
life of the E-peptides, synthetic EA and EB were incubated in growth media containing 10% 
FBS, and aliquots were taken for immunoblotting at various time points (Figure 2-7 D-F). While 
EA showed no signs of instability, EB clearly and quickly degraded. In fact, it is apparent that EB 
after 2 hours was a smaller size than the initial peptide, and the peptide at 30 minutes appears as a 
doublet. We believe that the full-length peptide is cleaved at the potential cleavage site located at 
the exon 5/6 boundary. A 2-phase exponential decay showed that the half-life of the full-sized 
peptide is 20 minutes, and the half-life of the remaining peptide is approximately 40 hours. So, 
EB may delay differentiation, but synthetic EB cannot be tested in our assay due to instability.  
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Figure 2-7 
 
 
 
Figure 2-7. E-peptides inhibit myoblast differentiation. A-C. C2C12 cells were grown to 
confluency and switched to differentiation media (Day 0). Media was changed every day and 
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synthetic peptides (100nM) were added to the fresh media. Quantitative RT-PCR was used to 
measure expression of differentiation markers: MyoD (Myod, A), Myogenin (Myog, B), 
Embryonic Myosin (Myh3, C). Expression of the markers at Days 1, 2, and 3 were compared to 
Day 0 to obtain fold change. Bars represent fold change means ± s.e.m. of N=3 replicates. *, 
p<0.05 for fold change expression comparisons via 2-way ANOVA followed by a Bonferroni 
post-test. D. Synthetic EA and EB peptides were incubated with growth media and aliquots were 
taken at times indicated for immunoblotting analysis. E-F. Quantification of (D) and analysis of 
peptide half-life. Bars represent percent of original intensity ± s.e.m. of N=3 replicates.  
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Discussion  
 Previous reports contend that the C-terminal E-peptide of the rodent igf1b gene splice 
form harbors an additional growth factor, MGF/EB, that acts independently of IGF-I. We 
challenged this hypothesis by comparing both C-terminal E-peptides, EA and EB, and by using a 
pharmacologic approach to decrease IGF-IR activity. Similar to past studies, we observed 
increased MAPK signaling that was concentration dependent and specific to the E-peptides. 
However, in contrast to those findings, we demonstrated that these signals were dependent upon 
the availability of IGF-IR. We extended this observation to determine if this was through direct 
activation of the receptors, which was not the case. Instead, the presence of the E-peptides 
significantly enhanced IGF-I mediated receptor phosphorylation, in part through increasing the 
proportion of receptors on the cell surface. By increasing the available pool of receptors for 
ligand binding, there was greater receptor activation. Next, we evaluated the IGF-I dependent and 
independent effects of rodent IGF-I E-peptides on the cellular processes necessary for muscle 
formation. We found that both E-peptides are mitogens in skeletal muscle cell culture, and that 
EB is more potent in driving proliferation and migration compared to EA. Not only do these 
actions require the MAPK pathway, E-peptide activity is also dependent upon IGF-IR signaling. 
Hence, in contrast to previous studies demonstrating IGF-I independent actions of MGF/EB, we 
find that the E-peptides coordinate with IGF-I at several key points during muscle growth. In fact, 
all of the E-peptide effects we have observed depend upon IGF-I and IGF-IR. We have now 
excluded independent activity through pharmacologic ablation of IGF-I receptor activity, and 
suggest that the E-peptides work in concert with IGF-I. Thus, we assert that the E-peptides are not 
independent growth factors, but instead are modulators of IGF-I actions. 
 To examine the effects of E-peptides, we synthesized peptides that reflected products of 
the igf1 gene. Synthetic rodent MGF, which has been tested in previous studies, contains the last 
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25 amino acids in IGF-IB beginning at the exon 4/5 boundary (Figure 2-1 A and B), so it shares 
no sequence homology with EA. While these residues may contain the active domains of EB, 
there is no evidence that MGF at this size exists in vivo, since there are no known cleavage 
recognition sequences between Exons 4 and 5 (5, 43). For these reasons, we included the residues 
encoded by Exon 4 in both EA and EB to mimic the predicted processing of the IGF-I proprotein 
(23). Even so, the effects of synthetic EB are similar to those with MGF (49, 76), and so it is 
likely that the N-terminal portion of EB is dispensable in terms of activity. Both E-peptide 
sequences contain a high percentage of polar and basic amino acid residues. To eliminate the 
possibility that the effects we observed were simply due to the presence of a charged peptide, we 
generated a random sequence, Scramble (Scr), based on the average charge and residue content of 
both E-peptides. Because Scr did not affect any of the processes we studied, even up to 1 µM, we 
are confident that the changes we observed after exposure to EA or EB were due to the specific 
sequences within these peptides.   
 While the synthetic E-peptides afford evaluation of their activity at exact concentrations 
and durations, there are some biological drawbacks. For example, the rodent EA peptide contains 
two potential glycosylation sites (* in Figure 2-1 B). Synthetic EA does not have glycosylated 
asparagine residues. If the glycosylation on EA is important for its mitogenic actions, then we 
will not see all of EA’s biological activity. An additional issue is that the instability of EB, which 
has a potential protease cleavage site at the exon 5/6 boundary, may abbreviate its activity (5). In 
fact, we found that the half-life of full-length synthetic EB is only 20 minutes, which may explain 
why we did not observe differentiation effects by EB over the course of a 3-day experiment 
(Figure 2-7). However, the shorter EB form likely has some mitogenic activity, as EB affected 
proliferation over a 24-hour treatment period, and enhanced ERK1/2 phosphorylation up to 30 
minutes after treatment. Alternate strategies to prevent degradation by replacing residues in the 
cleavage site can prolong synthetic EB half-life, and enable longterm studies of its actions. For 
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example, human myoblast senescence was delayed by modified MGF/EB (34). Nevertheless, the 
actions in vivo are likely curtailed by protease disruption of the peptide. 
 To our knowledge, we are the first to show that E-peptides augment IGF-IR activation by 
IGF-I, alter IGF-IR localization, and that E-peptide biological actions are dependent on IGF-I 
receptor activity. Both E-peptides increased IGF-IR phosphorylation and downstream MAPK 
signaling, but the E-peptides cannot increase ERK phosphorylation, proliferation, or migration 
when IGF-IR is inhibited. The E-peptides require a functional IGF-IR, but do not directly activate 
this receptor alone: IGF-I is required for the E-peptides to increase IGF-IR phosphorylation. 
Having excluded a direct E-peptide/IGF-IR activation mechanism, we addressed how this 
activation enhancement might occur through other means. One clue arises from the pattern of 
signaling following E-peptide exposure. E-peptides alone increase MAPK signaling, but not the 
Akt/PI3Kinase signaling arm. Because receptor internalization leads to increased P-ERK1/2 (13), 
the E-peptides may affect receptor internalization, thereby increasing the MAPK arm of the IGF-
IR pathway. Consistent with this possibility, we previously observed that the presence of E-
peptides enhanced IGF-I uptake (an indicator of receptor internalization) in myoblasts (52). We 
thus examined the localization of the IGF-IR on E-peptide and IGF-I treated cells. Instead of 
finding decreased cell surface IGF-IR, an indicator of receptor internalization, we found that the 
E-peptides upregulated the proportion of IGF-IR on the cell surface. Consistent with the ~30% 
increase in IGF-IR phosphorylation, we observed a ~40% increase in cell surface IGF-IR after E-
peptide treatment, compared to IGF-I alone. Increased surface receptor raises the amount of 
receptor available for IGF-I binding and activation. Thus, one mechanism by which the E-
peptides augment IGF-IR phosphorylation is by increasing the bioavailability of the IGF-IR.   
 Additionally, when EA or EB and IGF-I were used to stimulate myoblasts, the E-peptides 
amplified phosphorylation of ERK1/2, but not Akt. In addition, there was a significant 
enhancement of P-ERK2 between EA+IGF-I vs. EA alone. This effect is consistent with the 
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KIRA results shown in Figure 4, where IGF-IR phosphorylation by IGF-I was enhanced by 30% 
with the addition of E-peptides, and supports that the effects of the E-peptides occur through the 
IGF-IR. However, we cannot exclude the possibility that the E-peptides also work indirectly to 
enhance P-ERK1/2 through and IGF-IR independent mechanism. It should be noted that the MEK 
inhibitor blocked the E-peptide effects on migration and proliferation, confirming that if the E-
peptides act downstream of the IGF-IR, it is above MEK. Regardless of where the E-peptides 
affect IGF-IR signaling, enhancement of the MAPK arm but not the Akt/PI3K arm suggests that 
the E-peptides may help to tune the IGF-IR signaling cascade towards MAPK. The concept of 
receptor tuning has been shown in previous work. For instance, the level of receptor 
ubiquitination shifts not only its internalization but also the level of MAPK activation (28, 68). 
Further, specific regions of IGF-IR have been shown to be important for MAPK but not Akt/PI3K 
pathways (62), and an IGF-IR growth inhibitor has been found to activate ERK signaling through 
the IGF-IR, but not Akt (68). Increased IGF-IR bioavailability on the cell surface leading to 
increased IGF-IR phosphorylation cannot explain the tuning of the receptor. However, if the E-
peptides increase cell surface IGF-IR via enhancing the rate of IGF-IR recycling to the cell 
surface after internalization, it is possible that the E-peptides accelerate receptor internalization, 
thus tuning IGF-IR signaling. More direct methods of monitoring receptor trafficking could be 
used in future studies to track the kinetics of receptor movement.  
 Several studies have utilized IGF-IR neutralizing antibodies to block IGF-I signaling, and 
found that MGF can increase proliferation independently of IGF-IR (3, 48, 76). Neutralizing 
antibodies bind to the IGF-I recognition site on an extracellular domain of IGF-IR, and block 
IGF-I from binding to and activating its receptor. They can also, however, lead to receptor 
internalization and degradation (13, 30). This can activate or change the localization of IGF-IR, 
which confounds the interpretation of the results, especially since we found that IGF-IR 
localization changes in the presence of E-peptides. To avoid these problems, we used an IGF-IR 
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kinase inhibitor, NVPAEW541 (NVP) (27). NVP blocks the tyrosine kinase autophosphorylation 
that occurs on the intracellular portion of IGF-IR after ligand binding. By using this inhibitor, 
IGF-IR localization, levels, and basal signaling do not change, and IGF-I binding is unaffected. 
These methodological differences may underlie our ability to detect the E-peptide dependence on 
IGF-IR for signaling, proliferation, and migration.  
 A second objective of this study was to compare EA and EB, since EA has never been 
studied. We took advantage of previous demonstrations that MGF/EB affects myoblast signaling, 
proliferation, migration, and differentiation. It was completely unknown if EA shared or opposed 
any of MGF/EB’s effects. Previous studies have shown that MGF/EB increased ERK1/2 
phosphorylation (35, 53, 66). EB treatment increased ERK1/2 phosphorylation at low 
concentrations, but ceased to have activity at concentrations 100nM and higher. This pattern is 
not unusual, however, as other factors have been known to stimulate MAPK signaling in a 
bimodal fashion (11). Our signaling results show that while EB is more potent at activating 
ERK1/2 both in dose and duration, EA also increases P-ERK1/2. In addition, both EA and EB 
increased IGF-IR phosphorylation, localization, and downstream signaling when IGF-I was 
present. Thus, this study demonstrates clear overlap in the actions of the E-peptides.  
 One limitation to studying the E-peptides is that they have only been detected in vivo as 
part of pro-IGF-I (16, 17, 71), and so attributing any biological activity to the E-peptides 
independent of IGF-I has been met with skepticism. Although it is unknown at what 
concentration the free E-peptides are found, one can estimate their levels based on IGF-I 
concentrations. In an adult, IGF-I circulates in serum at ~ 50nM (6, 61). Given that for each 
mature IGF-I protein there is one E-peptide produced, and alternative splicing under normal 
conditions generates 90% of the igf1 in the A form (39), serum EA would be approximately 
45nM while EB would only be at 5nM. The underlying assumption is that the E-peptides enter 
the circulation similarly to IGF-I, and that they are stable, but given the short half-life of EB, it is 
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unlikely to accumulate in tissues or the blood. Further, both predicted levels are below the 
sensitivity for detection by EA (71) or EB antibodies (54). Thus, establishing that the E-peptides 
exist in vivo is difficult, at best. Our data support that the E-peptides work with IGF-I to modulate 
activity. The simplest way for this to occur is if they were still bound together as pro-IGF-I, 
which occurs in vivo (16, 17, 71). Thus, while others have argued for independent actions of the 
E-peptides, we assert that a more plausible model is that E-peptide “activity” reflects actions of 
pro-IGF-I. 
 MGF is thought to activate satellite cells and increase proliferation at the expense of 
differentiation. The process by which MGF works has been deemed the “MGF hypothesis” 
(reviewed in (5, 43)). According to the hypothesis, there is preferential splicing to produce the 
igf1b isoform immediately after muscle exercise or injury. Increased MGF/EB then activates 
satellite cells and promotes their proliferation. While the cells are proliferating, RNA processing 
reverts back to predominantly igf1a isoforms, causing MGF/EB levels to decrease, and allowing 
differentiation to proceed and repair the injured muscle. Our results are, in part, consistent with 
this hypothesis, because we also observe that EB increases myoblast proliferation. If the return to 
igf1a expression marks a switch between cell division and cell maturation, one would presume 
that EA would drive the next steps in muscle formation, namely differentiation and fusion, rather 
than continue to enhance proliferation. However, the inhibitory effects of EA on differentiation 
do not fit with this model. Also, in a recent study, specific targeting of either igf1a or igf1b 
delayed myoblast differentiation (42), suggesting that both E-peptides are necessary for normal 
differentiation. However, this would imply that increased EA or EB would enhance 
differentiation, contrary to our results. EB may possess much of the activity proposed in the MGF 
hypothesis, but EA shares similar activity. 
 Clearly, IGF-I and the E-peptides are not the sole determinants of the muscle formation 
process. Several additional growth factors are involved, and in some cases may be more efficient 
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in driving these steps. For example, MGF/EB actions on myoblast migration have been attributed 
to the modulation of the matrix metalloproteinases (MMPs) (49), which are important regulators 
of muscle remodeling (reviewed in (12)). We, too, have found that EB enhances expression of 
MMP13, an interstitial collagenase important for wound healing (7, 72, 73). Whether or not 
MMPs are one of the mechanisms involved in EB enhanced migration has not been addressed. 
However, since MEK inhibition did not completely block the migration response to EB, it 
suggests that other mechanisms coordinate with the MAPK pathway to mediate cell migration. 
 Could the E-peptides provide therapeutic benefit to muscle disease or damage? While 
IGF-I is widely recognized for its positive actions on muscle, modulatory factors such as the E-
peptides may augment tissue responses to IGF-I. However, the interactions between the multiple 
products of the igf1 gene extend beyond muscle growth. For instance, targeting E-peptide activity 
could also prevent IGF-I mediated actions, which is a critical strategy for several anti-cancer 
therapies (31). Regardless of the pro- or anti-growth intentions for IGF treatments, it is becoming 
clear that the E-peptides contribute to the actions of IGF-I, and should therefore be part of the 
equation for evaluation of IGF-I based therapies. Understanding the biological basis for E-peptide 
activity will help in clarifying IGF-I function. 
 
Materials and Methods 
Synthetic E-peptides 
Murine EA and EB (based from GenBank AY878192 and AY878193, respectively) were 
synthesized by Bio-Synthesis Inc., Lewisville, TX, and purified via HPLC to >95%. The final 
products were confirmed via MALDI mass spectrometry (Wistar Proteomics Facility, U of 
Pennsylvania, Philadelphia, PA). EA and EB peptides begin at histidine 78, immediately 
following the SPC cleavage site (23). The Scramble peptide sequence was created by randomly 
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selecting 31 amino acids from EA and EB sequences (Figure 1B). Peptides were provided in 
0.1mg lyophilized aliquots to avoid freeze-thaw cycles and stored at -80°C until time of use.  
Synthetic E-peptide signaling 
C2C12 (ATCC, Manassas, VA) cells were maintained in growth media (DMEM containing, 10% 
fetal bovine serum, and gentamicin). For signaling experiments, 2x104 cells were seeded in 6-well 
plates in growth media and allowed to attach and grow overnight. The next day, cells were 
starved overnight in growth media without serum. On the third day, cells were treated with 
synthetic E-peptides and/or recombinant human IGF-I (Gemini Bio-Products West Sacramento, 
CA) for the time periods indicated in figures, and the cells were processed for immunoblotting as 
described below. For IGF-IR inhibition, 100nM NVPAEW541 (27) diluted in DMSO or DMSO 
only was added to starved cells 90 minutes before and during treatment with synthetic peptides. 
Immunoblotting analysis 
Signaling pathway activation was determined by immunoblotting. Cells were washed in cold PBS 
before incubation in lysis buffer (50nM HEPES, 150nM NaCl, 5mM EDTA, 1nM EGTA, 15mM 
p-Nitrophenyl phosphate disodium hexahydrate, 1% NP-40, 0.1% SDS, 1% Deoxycholate, 
0.025% Sodium Azide) with protease and phosphatase inhibitors (P8340, P5726, Sigma, St. 
Louis, MO). Debris were pelleted, and the total protein was measured in the supernatant. Equal 
amounts of protein were separated by SDS-PAGE and transferred to polyvinylidene fluoride 
membranes (Immobilon-P, Millipore, Bedford, MA). Membranes were blocked in Tris-buffered 
saline (TBS) plus 0.1% Tween 20 (TTBS) and 5% nonfat dry milk. Membranes were incubated in 
primary antibody diluted in 5% milk-TTBS overnight at 4°C. The following antibodies were 
used: phospho-Akt (no. 9271), phospho-ERK1/2 (no. 9101), total ERK1/2 (no. 9102), GFP (no. 
2955) (Cell Signaling, Beverly, MA), and tubulin (T5168 Sigma). Membranes were washed in 
5% milk-TTBS and incubated with horseradish peroxidase-conjugated secondary antibodies. 
Protein detection was performed using enhanced chemiluminescence and the ImageQuant (GE 
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Fairfield, CT) detection system. Analysis of band intensity was performed using the associated 
image analysis software. Synthetic EA and EB stability was evaluated by incubating peptides in 
growth media at 37°C. Aliquots were obtained at 0-24 hours, and immunoblotted as above. An 
antibody to the EA peptide was generated by Bio-Synthesis Inc., Lewisville, TX and serum from 
the inoculated rabbit was used to visualize EA. An antibody to MGF/EB was used to visualize the 
EB peptide (54) . 
IGF-IR Activation and Location Assays  
To determine if E-peptides directly activate IGF-IR, a KIRA assay was preformed as previously 
described (20) with a few alterations. Briefly, 2.5x104 P6 cells, which overexpress IGF-IR (a kind 
gift from the Baserga lab (55)) were seeded into 96-well plates. They were maintained in growth 
media supplemented with 200 µg/ml G418. The cells were starved for 6 hours, and then treated 
with synthetic E-peptides and/or IGF-I for 15 minutes. Cells were lysed and IGF-IR was captured 
onto an ELISA plate coated with an antibody to IGF-IR (MAB1120, Millipore, Billerica, MA). 
An HRP-conjugated antibody to phosphorylated tyrosines (16-454, Millipore) and TMB substrate 
(N301, Thermo Scientific, Rockfort, IL) was used for colorimetric quantification. Absorbance 
was read at 450 nm via the SpectraMax M5 plate reader (Molecular Devices, Sunnyvale, CA), 
which served as an indicator of IGF-IR phosphorylation. The IGF-IR localization assay was 
based on (20, 58, 69) and preformed as described above, except after treatment and before lysis, 
cell surface proteins were labeled with 0.3 mg/ml sulfo-NHS-biotin (21217, Thermo Scientific, 
Rockfort, IL) in PBS for 1 hour at 4°C. Two ELISA plates coated as above were utilized. Half of 
the cell lysates were transferred to one plate to measure cell-surface IGF-IR, visualized by an 
HRP-conjugated strepavidin antibody. The remaining lysates were used on the second plate to 
measure total IGF-IR, by incubation with an IGF-IR antibody (C-20, Santa Cruz, CA) followed 
by an a HRP-conjugated anti-rabbit antibody. 
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Cell Proliferation 
Proliferation was measured using a 5-bromo-2P-deoxyuridine (BrdU) plate and slide assays 
(Roche, Indianapolis, IN). For the plate assay, 5x103 C2C12 cells were seeded in 96-well plates. 
Cells were starved for 6 hours, and treated with synthetic E-peptides or recombinant IGF-I 
overnight. BrdU was added for incorporation for 2 hours before cell lysis and BrdU staining. For 
MAPK inhibition, a MEK inhibitor was added to the media (PD 098059, Sigma, 50µM). For 
IGF-IR inhibition, 100nM NVPAEW541 was added to the media. The slide assay was done as 
above, except with 2x104 C2C12 cells in 24-well plates on glass cover slips. Cells were stained 
with an antibody to BrdU and with DAPI (VectorLabs, Burlingame, CA) to visualize nuclei. 
Images were acquired using a Leica DMR epifluorescence microscope using OpenLab imaging 
software (Improvision, PerkinElmer, Waltham, MA).  
Cell Migration 
E-peptide effects on cell migration were tested using a 24-well Transwell (8.0 µm pore size) plate 
assay (Corning Inc., Lowell, MA). C2C12 cells (2x104) were seeded in the upper chambers in 
serum-free media, and synthetic E-peptides in serum-free media were placed in the bottom 
chambers. Cells were allowed to migrate for 5 hours. Non-migrated cells remaining in the upper 
chamber were removed from the transwell membranes with Q-tips and migrated cells were fixed 
with 4% formaldehyde and stained with DAPI. The transwell membranes were mounted onto 
slides, and imaged at 10X using above-mentioned microscopy and analysis software. For MAPK 
signaling or IGF-IR inhibition, PD (50µM) or NVP (100 nM) was added to both chambers at the 
start of the experiment.  
Muscle cell Differentiation 
Cells were plated in 6-well plates and changed to differentiation media (DMEM containing, 2% 
horse serum, and gentamicin) when they reached 80-90% confluency (Day 0). Differentiation 
media was changed every day until Day 3. Synthetic E-peptides (100nM) were added to the 
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differentiation media once a day. Total RNA was isolated from differentiating cells using Trizol 
(Invitrogen, Carlsbad, CA). 
Quantitative RT-PCR 
Equal amounts of total RNA from each sample were subjected to single-strand reverse 
transcription (Applied Biosystems, Foster City, CA). The resultant cDNA was utilized for 
quantitative RT-PCR (qRT-PCR) with oligonucleotides specific for genes listed below using the 
Applied Biosystems 7300 Real-Time PCR System, and reagents (Power SYBR Green PCR 
Master Mix). All samples were loaded in duplicate in 96-well plates. Expression of 18S was used 
to control for cDNA content. Fold change was calculated by comparing ∆CT values for each gene 
at each Day to ∆CT at Day 0. Primers used: 18S, 5'-ctctgttccgcctagtcctg-3' and 5'-
aatgagccattcgcagtttc-3'; MyoD, 5'-tgctcctttgagacagcaga-3' and 5'-agtagggaagtgtgcgtgct-3'; 
Myogenin, 5'-gggcccctggaagaaaag-3' and 5'-aggaggcgctgtgggagt-3'; Embryonic myosin, 5'-
gcatagctgcacctttcctc-3' and 5'-cgtgtatcggtccttgaggt-3'; IGF-I, 5'-cacacctcttctacctggcgctctgc-3' and 
5'-agtctcctcagatcacagctccg-3'. 
Statistical Analysis 
All data was analyzed via student t-tests, 1-way ANOVA followed by a Tukey post-test, or by 2-
way ANOVA followed by a Bonferroni post-test. Statistical significance was accepted at p < 
0.05.  
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Abstract 
Insulin-like growth factor-I (IGF-I) is a potent growth factor that regulates and 
promotes growth in skeletal muscle. IGF-I is synthesized as a precursor protein that 
requires proteolytic processing to produce the mature growth factor. The full-length IGF-
I precursor polypeptide is called pre-pro-IGF-I, and contains a signal peptide, mature 
IGF-I, and a C-terminal extension called the E-peptide. Alternative splicing gives rise to 
different IGF-I isoforms, and in the rodent and other non-primate mammals, there are two 
isoforms, called IGF-IA (IA, containing E-peptide A, EA) and IGF-IB (IB, containing E-
peptide B, EB). The mature IGF-I produced by both isoforms is identical, while EA and 
EB share less than 50% homology. The purpose and activity of the E-peptides is 
unknown, but studies focusing on E-peptide activity in muscle cell culture have found 
that EB can increase the proliferation and migration of myoblasts, and  it has been 
implicated in satellite cell activation. While the expression of igf1 RNA isoforms has 
been studied extensively in muscle, E-peptide activity has not been evaluated in vivo. In 
this study, we compare the effects of expressing EA and EB in vivo using recombinant 
self-complementary Adeno-associated virus (AAVsc) vectors to express the IGF-I 
isoforms mutated at Valine 44 to Methionine in mouse skeletal muscles. This mutation  
renders the IGF-I non-functional, but the E-peptides are not affected. IGF-I V44M retains 
its processing and 3D structure, and so the E-peptides produced from IGF-I V44M 
constructs are processed like endogenous E-peptides, but there is no additional functional 
IGF-I expressed. By injecting the AAVsc vectors into mouse hindlimbs, we determined 
the effects of E-peptide expression in skeletal muscle, and found that both E-peptides 
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affect muscle signaling and reduce satellite cells. IB V44M expression initially induces 
hypertrophy by increasing the fiber area of MHC2B fibers, but long-term expression led 
to weakened muscles. Thus, although EB induces more hypertrophy than EA, extended 
EB treatment may have detrimental effects. 
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Introduction 
Insulin-like growth factor-I (IGF-I) has endocrine, autocrine, and paracrine 
activity due to its release into the circulation from the liver, and its local production and 
secretion in various tissues, including skeletal muscle. When the IGF-I receptor (IGF-IR) 
is specifically inactivated in skeletal muscle, muscles are 10-30% smaller (25), and 
increasing the levels of IGF-I leads to hypertrophy (1, 12, 16, 38). Thus, IGF-I is one of 
the major growth factors that directs skeletal muscle growth. 
IGF-I regulates muscle growth via binding to and activating IGF-IR, which 
initiates multiple signaling cascades (42). IGF-IR activation triggers the MAPK pathway, 
which includes ERK1/2 phosphorylation, increasing proliferation and migration in 
satellite cells and myoblasts. The PI3-Kinase/Akt pathway is also stimulated, which leads 
to increased differentiation and protein synthesis in mature muscle fibers (19, 30, 31). 
When muscle tissue grows during regular growth or with exercise, or when 
muscle is damaged by injury or overload, the muscle fibers must increase in size. This 
hypertrophy requires increased protein synthesis, which in turn requires additional nuclei. 
Since muscle fibers are post-mitotic, growth and regeneration rely on a stem cell-like 
niche of quiescent pre-muscle cells called satellite cells. Satellite cells are located 
between the basal lamina surrounding muscle fibers and the fiber cell membrane (35), 
and remain quiescent until needed for growth or repair. Once activated by growth signals, 
overload, or injury, the satellite cells proliferate, migrate to the region of the muscle that 
requires extra nuclei, and differentiate by fusing with myofibers (26). 
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The general consensus is that all IGF-I activity is mediated by mature IGF-I, but 
IGF-I is synthesized as a precursor protein that requires proteolytic processing at the N- 
and C-termini to produce the mature growth factor (29). The full-length precursor 
polypeptide is called pre-pro-IGF-I and contains a signal peptide, mature IGF-I, and a C-
terminal peptide called the E-peptide. After signal peptide removal in the ER, the 
polypeptide including IGF-I and the E-peptide is called pro-IGF-I. Proprotein convertases 
like furin can cleave pro-IGF-I, resulting in free mature IGF-I and an E-peptide (22-24). 
In addition, pro-IGF-I has been found in cell culture media and in vivo in serum (11, 17, 
18, 46, 55), indicating that IGF-I can be secreted while still attached to an E-peptide.  
Alternative splicing gives rise to the different IGF-I isoforms, and the critical 
splicing event that determines which pro-IGF-I isoform is expressed occurs at the 3’ end 
of the igf1 gene. In the rodent and other non-primate mammals, there are two isoforms, 
called IGF-IA (IA) and IGF-IB (IB). The difference in the isoforms is due to the 
exclusion (IA) or the inclusion (IB) of exon 5, a short 52 nucleotide cassette exon (13, 
49) (Figure 3-1A-B). The splicing only affects the E-peptide, and so the mature IGF-I 
from both isoforms is exactly the same, while IA isoforms give rise to E-peptide A (EA) 
and IB isoforms produce E-peptide B (EB). The predominant igf1mRNA isoform 
expressed is igf1a, which is the most conserved across all species examined, and makes 
up 90-99% of the isoforms expressed (15, 32, 33, 50, 51, 54).  
 Studies have investigated E-peptide activity in muscle cell culture, and EB has 
been shown to increase the proliferation and migration of myoblasts, and it has been 
implicated in satellite cell activation (4, 28, 37, 56). Some of these activities were 
apparent even when a neutralizing antibody to IGF-IR was present (4, 37, 43, 52, 56), 
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suggesting that EB activity is IGF-I independent. However, our recent findings have 
shown that these activities depend on IGF-IR signaling and localization. Accordingly, it 
is necessary to determine if the E-peptides have activity independent of IGF-I and IGF-IR 
signaling, or if they are modifying IGF-I activity.  
While the expression of igf1 mRNA isoforms in muscle has seen studied 
extensively, E-peptide activity has not been evaluated in vivo. Our lab has sought to 
compare the IGF-I isoforms, and found that expressing IA, IB, or mature IGF-I only (ISt, 
no E-peptide) via Adeno-associated virus (AAV) vectors in mouse hindlimbs, causes 
different degrees of hypertrophy (8, 9). Interestingly, both IA and IB caused more 
hypertrophy when compared to expressing a mature IGF-I only (no E-peptide), implying 
that the E-peptide is necessary and important for proper IGF-I secretion, IGF-IR 
activation, or downstream signaling (9). However, these studies tested full-length IGF-I 
isoforms, which express IGF-I in addition to the E-peptides, and thus it difficult to 
discriminate E-peptide activity from IGF-I activity. 
In this study, we have sought to compare EA and EB expression in vivo without 
the expression of functional IGF-I. We used recombinant self-complementary Adeno-
associated virus (AAVsc) vectors to express the IGF-I isoforms mutated at Valine 44 to 
Methionine in mouse skeletal muscles. This is a naturally occurring mutation which 
renders the IGF-I non-functional, but the E-peptides are not affected (21). IGF-I V44M 
retains its processing and 3D structure, and so the E-peptides will be produced similarity 
to wildtype constructs, but there will be no addition of functional IGF-I. By injecting the 
AAVs into mouse hindlimbs, we determined if the E-peptides had similar activity in vivo 
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as they do in cell culture, focusing on signaling, hypertrophy, muscle strength, fiber size 
and type, and satellite cell proliferation. 
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Results 
V44M mutation eliminates IGF-I activity 
 When wildtype IGF-I IA, IB,  and IStop (no E-peptide, ISt), are expressed in 
mouse muscle using AAV vectors, the different isoforms cause different degrees of 
hypertrophy (8, 9). However, it is difficult to discern how much of that activity is due to 
the E-peptides, as the constructs produce IGF-I in addition to the E-peptides, and the 
activity of IGF-I could overshadow any E-peptide effects. Conversely, expressing only 
the E-peptide cDNA without the rest of the IGF-I gene could lead to E-peptide 
production that is not relevant to how the E-peptides are naturally expressed, processed, 
secreted, or stored. Thus, we sought to express the E-peptides in their native form and to 
test the E-peptides without increasing the levels of functional IGF-I, we took advantage 
of the naturally occurring mutation, Valine 44 to Methionine (21). We mutated previously 
cloned constructs (40) using site directed mutagenesis, to generate V44M forms of IA, 
IB, ISt (Figure 3-1 A-B) in the expression vector pIRES, which contains an IRES, 
followed by the cDNA for GFP. We transfected the wildtype and mutated plasmids into 
3T3 cells, and used the conditioned media in IGF-IR specific kinase receptor activation 
(KIRA) assays (20), to determine if the V44M mutation produced non-functional IGF-I 
(Figure 3-1 C). While wildtype IA, IB, and ISt constructs led to robust IGF-IR 
phosphorylation, the V44M constructs did not activate the receptor significantly more 
than media from cells transfected with an empty vector (GFP). Thus, V44M mutated 
IGF-I cannot activate the IGF-IR, and since nearly all recorded IGF-I activities utilize the 
IGF-IR, IGF-I V44M is effectively non-functional. 
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Figure 3-1 
 
Figure 3-1. IGF-I V44M isoform constructs do not activate IGF-IR. A. Alternative 
splicing at the 3’ end of the igf1 gene generates two isoforms: igf1a and igf1b. igf1a 
isoforms splice from exon 4 to exon 6, while isoform igf1b includes exon 5, leading to an 
82 
 
altered reading frame and earlier stop codon in exon 6. Exons not drawn to scale. B. 
cDNA constructs generated to express V44M versions of IGF-IA (IA, containing E-
peptide A), IGF-IB (IB, containing E-peptide B) and IGF-IStop (ISt, stop codon after 
IGF-I, no E-peptide). Dotted lines indicate mature IGF-I boundaries. V44M mutation is 
within the mature IGF-I sequence, and does not affect the E-peptide sequence. C. Ability 
of IGF-I and IGF-I V44M isoforms to activate IGF-IR. pIRES plasmids containing IGF-I 
isoforms were mutated using site-directed mutagenesis at Valine 44 to Methionine. 
Conditioned media from transfected 3T3 cells were used to stimulate IGF-IR over-
expressing fibroblasts (P6 cells), and IGF-IR phosphorylation was measured using a 
kinase receptor activation ELISA assay (KIRA) and normalized to GFP expression 
(immunoblot not shown) to control for transfection efficiency. GFP, transfection with 
empty pIRES plasmid. Bars represent means ± s.e.m. of N=3 replicates. *, p<0.05, for 
comparisons to GFP via 1-way ANOVA followed by a Tukey post-test. D. IGF-I V44M 
isoforms were cloned into pAAVsc-CB plasmids for AAV generation. ITR, AAV 
inverted terminal repeat sequence; CMV, cytomegalovirus; SV40, Simian virus 40; BGH, 
bovine growth hormone. 
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AAVsc-V44M vectors express IGF-I isoforms 
 To express the E-peptides in vivo, we cloned the V44M cDNAs into pAAVsc-CB 
plasmids to generate self-complementary Adeno-associated virus (AAVsc) vectors 
(Figure 3-1 D). Targeting the Tibialis anterior (TA) and Extensor digitorum longus 
(EDL) muscles, the anterior hindlimbs of young (2-3 week old) C57 mice were injected 
with AAVsc-IGF-I V44M isoforms IA, IB, or ISt. After 1 month of expression, muscles 
were tested via ELISA (Figure 3-2 A) and immunoblotting (Figure 3-2 B) to determine 
the amount and the forms of IGF-I expressed. All three V44M IGF-I isoforms produced 
more IGF-I than uninjected limbs (Figure 3-2 A), however, ELISA measurements 
indicate that the ISt V44M construct produced 10-fold more IGF-I than IA or IB V44M.  
 To confirm that the correct forms of IGF-I were produced, muscle lysates were 
immunoblotted with IGF-I, EA, and EB-specific antibodies (Figure 3-2 B-C). The IGF-I 
antibody reacted strongly with bands in ISt, IA, and IB V44M lanes. ISt only produced a 
band at 7-8 kD, the size of IGF-I in serum and tissues (11, 48) (Figure 3-2 B), which was 
not immunoreactive with EA or EB antibodies (Figure 3-2 C). IA V44M expression 
generated multiple bands from 12-22 kD in both IGF-I and EA antibody blots. These 
bands represent pro-IA, and pro-IA with one glycosylated asparagines, and pro-IA with 2 
glycosylated asparagines (6). One single band at 14 kD can be seen in the IB V44M lane 
with both IGF-I and EB-specific antibodies, and represents pro-IB. Based on the sizes 
and antibody reactivity, AAVsc IGF-I V44M injections give rise to the correct IGF-I 
isoforms, and thus produce the intended E-peptides. 
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Figure 3-2 
 
Figure 3-2. AAVsc IGF-I V44M isoform injections lead to increased IGF-I 
production in muscle after 1 month. A. IGF-I ELISA on AAV injected TA muscles. 
Bars represent means ± s.e.m. of N=5 muscles per injection. *, p<0.05, for comparisons 
to Uninjected or †, p<0.05, for comparisons to ISt V44M via 1-way ANOVA followed by 
a Tukey post-test. B. IGF-I V44M isoform immunoblot. Lysates from TA muscles 
injected with AAVs were immunoblotted with an IGF- I antibody. C. Lysates were also 
immunoblotted with EA and EB specific antibodies, to confirm the expression of the 
correct isoforms.  GAPDH was used as a loading control. For B and C: a and b, doubly 
and singly glycosylated pro-IA; c, pro-IB; d, unglycosylated pro-IA; e, mature IGF-I; f, 
GAPDH.  
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IA and IB V44M expression increases MAPK and IB V44M reduces Akt phosphorylation 
 We previously reported that the E-peptides modulate muscle cell signaling that 
relies on the IGF-IR. Namely, the E-peptide increase the activation of MAPK signaling 
pathway, but not the PI3K/Akt pathway, which are both downstream from IGF-IR 
activation (Chapter II). To see if IA or IB V44M could also activate these pathways, 
young mice were injected with the AAV vectors, and muscles were harvested for 
immunoblotting 7 days later (Figure 2-3). Each mouse was injected with AAVsc ISt 
V44M as a negative control in one limb (control limb). The ISt V44M injection produces 
the mutated IGF-I, but no E-peptide, and will allow confirmation that mature IGF-I 
V44M has no activity in muscle nor dominant-negative effects on normal IGF-I. Either 
AAVsc IA V44M, IB V44M, or needle-prick only (Uninj) were injected into the other 
limb (test limb), allowing for paired comparisons between limbs.  
 The mature IGF-I V44M did not affect signaling, as there was no significant 
difference between ISt V44M and uninjected limbs for ERK or Akt phosphorylation. 
Both IA and IB V44M injected limbs contained higher levels of phosphorylated ERK1/2 
(P-ERK1/2), a marker for MAPK pathways activation. While IB V44M increased both P-
ERK 1 and 2 by 2-fold, IA V44M was more potent, with an 8-fold increase for ERK1, 
and a 3-fold increase for ERK2. Most interestingly, while IA V44M had no significant 
effect on the PI3K/Akt pathway, IB V44M expression led to a reduction in 
phosphorylated Akt (P-Akt). So, both E-peptides affect two major signaling pathways in 
muscle.  
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Figure 3-3 
 
Figure 3-3. E-peptides affect muscle signaling. A. Mouse hindlimbs were injected with 
AAVsc vectors harboring IA V44M , IB V44M, or uninjected in one limb, with ISt 
V44M injected in the contralateral limb. TA lysates were immunoblotted for 
phosphorylated and total ERK1/2 (P-ERK, T-ERK) and phosphorylated and total AKT 
(P-Akt, Total Akt not shown). Two mice per treatment are shown. Bars above injection 
show the paired TAs from one mouse. B-D. The intensities of phosphorylated bands were 
normalized to total bands, and then compared to the ISt V44M control TA. Bars represent 
means ± s.e.m. of N=3-4 mice per test injection. *, p<0.05, for comparisons to ISt V44M 
control limbs via paired t-tests. 
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IB V44M expression causes hypertrophy 
 To allow time for the E-peptides expressed to affect muscle mass and/or strength, 
wildtype mice were injected as in Figure 3-2, but sacrificed 1 month later. The mass, 
cross-sectional area (CSA), maximan tetanus force, and specific force were analyzed in 
the EDL muscles (Table 3-1). ISt V44M injected limbs were not significantly different 
from uninjected limbs in any of the parameters analyzed (Table 3-1), indicating that 
mature IGF-I V44M was in fact non-functional in vivo. IA V44M did not cause any 
hypertrophy, but increased the specific force slightly and significantly compared to ISt 
V44M injected controls. The CSA in IB V44M injected muscles was significantly larger 
than ISt V44M control limbs by ~6%, while the mass was increased by ~5%. In addition, 
the maximal tetanus force was increased by ~5% with IB V44M expression, but once 
normalized to CSA for specific force, this difference was no longer evident. Therefore 
the increase in strength was due to the hypertrophy (Figure 3-4 A), and not a change in 
muscle architecture. 
The hypertrophy caused by IB V44M expression could be transient. Also, it could 
take longer for IA V44M to affect muscle size. For these reasons, wildtype mice were 
injected as in Figure 3-2, and sacrificed 3 months after injection (Table 3-1 and Figure 3-
4 B). Here, IA V44M injected EDLs were larger than ISt V44M injected controls, but the 
difference did not reach significance (7% CSA and 3% mass). IB V44M injected limbs 
were still significantly larger than ISt V44M controls by 10% CSA and over 6% for mass. 
This shows that the EB induced hypertrophy for a sustained period of time. Interestingly, 
the IB V44M injected EDLs were weaker than controls in both tetanus and specific force, 
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indicating that although the muscles are bigger, EB could negatively affect muscle 
strength after long periods of exposure. 
 
IB V44M hypertrophy depends on IGF-IR 
 In cell culture, EB requires a functional IGF-IR to increase myoblast MAPK 
signaling, proliferation, and migration. Accordingly, we sought to determine if IB V44M 
activity in vivo, namely muscle hypertrophy, also requires IGF-IR. We injected MKR 
mice, which express a dominant negative IGF-IR in mature skeletal muscle, as in Figure 
3-4 A. In muscle without functional IGF-IR, EB had no affect on muscle mass or strength 
(Table 3-1 and Figure 3-4 C). Additionally, IA V44M did not increase EDL specific 
force. Therefore, E-peptide activity in vivo requires functional IGF-IR. 
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Figure 3-4 
 
Figure 3-4. IA and IB V44M expression affects muscle mass. A-C. The masses of 
AAV IA or IB V44M EDLs were compared to the mass of the ISt V44M control EDLs. 
The percent change in mass is graphed. Wildtype C57 mice dissected 1 (A) and 3 (B)  
months after injection; MKR mice which do not express functional IGF-I in skeletal 
muscle, dissected 1 month after injection (C). Bars represent means ± s.e.m. of N=4-8 
EDL muscle pairs per injection. *, p<0.05, for comparisons to ISt V44M contralateral 
control EDLs via paired t-tests.   
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Larger fibers responsible for IB V44M hypertrophy 
 IGF-I treatment induces hypertrophy that is characterized by an increase in 
muscle fiber area (1, 12, 16). To determine if the V44M constructs affected fiber size, 
sections from EDL muscles were stained to outline fibers, and fiber areas were analyzed 
(Figure 3-5). Neither ISt V44M nor IA V44M had an effect on fiber area, while the fiber 
area distribution for IB V44M fibers was shifted to the right compared to the ISt V44M 
control fibers (Figure 3-5 D). When the average fiber area for each EDL was compared to 
the fibers in the contralateral ISt V44M EDLs, the IB V44M fibers were significantly 
larger by 20%.  
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Figure 3-5 
 
 
 
Figure 3-5. Fiber area increases after AAVsc IB V44M injection. A. Sections of 
AAVsc V44M injected EDLs were stained for dystrophin (green) to outline muscle 
fibers, and DAPI (blue) to show nuclei. Scale bar = 65 µm. B-D. The area of all the fibers 
in the EDLs (~1000 fibers on average per EDL) were measured and histograms were 
generated prepresenting the proportion of fibers at a certain area. E. The percent change 
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in average fiber area compared to ISt V44M control limbs is graphed. Bars represent 
means ± s.e.m. of N=5 EDL muscle pairs per vector. *, p<0.05, for comparisons to ISt 
V44M contralateral control EDLs via paired t-tests.   
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IB V44M hypertrophy affects predominantly 2B fibers 
 Skeletal muscles contain different fiber types, categorized by the type of Myosin 
Heavy Chain (MHC) they express. It seemed likely that IB V44M caused hypertrophy 
specifically in MHC2B fibers, as the EDL is a fast-twitch muscle and contains mostly 2B 
fibers. Also, we observed no hypertrophy in AAVsc IB V44M injected Soleous muscles 
(data not shown), a muscle type that contains mostly slow-twitch MHC1/β fibers (2, 5). 
To test if IB V44M only causes hypertrophy in a specific muscle type, the area of MHC1/ 
β, 2A, and 2B fibers were determined. The right-ward shift in IB V44M fiber 
distributions was most pronounced in 2B fibers and there was a less pronounced 
rightward shift for 2A fibers. There were too few 1/β fibers to generate a histogram. The 
average fiber size of 2B fibers was significantly larger than ISt V44M controls by 25%, 
while the 1/β and 2A fibers were not significantly affected by IB V44M expression 
(Figure 3-6 C), indicating that EB induced hypertrophy predominantly affects 2B fibers. 
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Figure 3-6 
 
Figure 3-6. MHC2B fibers are larger in IB V44M expressing muscles. A. Laminin 
(red) was labeled in muscle sections to outline fibers and MHC-specific antibodies were 
used to label I/β, 2A, and 2B fibers (green). B-C. The areas of the different fiber-types 
were measured and histograms were generated as in Figure 3-5. There were not enough 
1/β fibers to generate a histogram. D. The average fiber area of all fibers, and of each 
fiber-type are graphed. Bars represent means ± s.e.m. of N=5 EDL muscle pairs. *, 
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p<0.05, for comparisons to ISt V44M contralateral control EDLs via paired t-tests. E. 
Mice injected with AAVsc IB and ISt V44M for 1 month were treated with 
Dexamethasone (DEX) or not treated (NoTx) for 2 weeks before dissection to cause 
glucocorticoid-induced atrophy. Bars represent means ± s.e.m. of N=5-6 EDL muscle 
pairs. †, p<0.05 or ns, not significant, for comparisons to ISt V44M contralateral control 
EDLs via paired t-tests; *, p<0.05, for comparisons to NoTx via unpaired t-test.  
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IB V44M expression cannot prevent glucocorticoid-induced atrophy 
 Because EB expression led to 2B fiber hypertrophy, it could be possible for 
AAVsc IB V44M injections to prevent 2B-specific atrophy. Glucocorticoids cause 
general atrophy in mice, but in muscle, 2B fibers are the most affected fiber type (2). 
Therefore, wildtype mice were injected with IB V44M in one limb and ISt V44M in the 
contralateral limb for 1 month, and two weeks before dissection, mice were untreaed 
(NoTx) or treated with dexamethasone (DEX) in their drinking water (Figure 3-6). DEX 
treatment caused a reduction in body, spleen, and EDL mass (31%, 50%, and 25% 
respectfully). As in Table 3-1, IB V44M expression caused a ~5% increase in EDL mass 
in NoTx mice. However, while IB V44M injected EDLs in DEX treated mice were 
slightly larger than ISt V44M injected EDLs, the difference was not significant. In 
addition, both ISt and IB V44M injected limbs were smaller in DEX treated mice, and so 
even though IB V44M can cause hypertrophy in healthy wildtype muscle, it cannot 
prevent atrophy. 
 
E-peptides reduce satellite cell number 
 EB has been reported to activate satellite cells and increase their proliferation in 
culture (4, 28, 37, 56). To examine if increasing E-peptide expression in muscle affects 
satellite cells and their proliferation, the number of satellite cells (Pax7 positive nuclei), 
proliferating cells (Ki67 positive nuclei), and proliferating satellite cells (both Pax7 and 
Ki67 positive nuclei) were counted in EDL sections after 1 month of IA, IB, or ISt V44M 
expression (Figure 3-7). ISt V44M expression had no affect on satellite cell, proliferating 
cell, or proliferating satellite cell number compared to uninjected controls. IA and IB 
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V44M had no effect on the number of proliferating cells, or proliferating satellite cells. 
This is surprising, as EB has been shown to increase proliferation in many different cell 
types including satellite cells and myoblasts (4, 37, 56). Even more surprising, both E-
peptides caused a reduction in the total number of satellite cells. It seems that in vivo, the 
E-peptides negatively affect satellite cell number. 
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Figure 3-7 
 
Figure 3-7. E-peptides reduce satellite cell number. A. Nuclei (DAPI, blue), 
proliferating nuclei (Ki67, red) and Satellite cell nuclei (Pax7, green) were labeled in 
AAVsc IA, IB, and ISt V44M injected EDL muscles. *, Quiescent satellite cell; ►, 
activated, proliferating satellite cell. B-C. The number of Ki67 positive nuclei (B), Pax7 
positive nuclei (C), and the number of both Pax7 and Ki67 positive nuclei (D) per 100 
fibers. Bars represent means ± s.e.m. of N=4-6 EDL muscle pairs per vector tested. *, 
p<0.05, for comparisons to ISt V44M contralateral control EDLs via paired t-tests.   
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Discussion 
 In this study we evaluated the ability for IGF-I E-peptides, expressed with a non-
functional IGF-I, to affect muscle signaling, mass, strength, and satellite cell number and 
proliferation. We report that both E-peptides affect muscle signaling and reduce satellite 
cells. IB V44M expression induces hypertrophy by increasing the fiber area of MHC2B 
fibers. However, after three months of expression, muscles injected with IB V44M were 
weaker than controls, suggesting that long-term treatment with EB may cause 
hypertrophy but at the expense of muscle strength. 
As in our previous studies, we utilized AAV to express our constructs in muscle. 
In this study, we took advantage of self-complementary AAV. AAVsc vectors initiate 
gene expression rapidly (36), and with our vectors, IGF-I is produced within days after 
injection (39). In addition, the IGF-I isoforms used in this study were driven by the 
chicken β-actin promoter, which is not a muscle-specific promoter. We chose this 
promoter because it drives robust transgene expression, and as IGF-I and the E-peptides 
are secreted proteins, this study did not require that expression be limited to muscle cells. 
 The IGF-I pre-pro-peptide is consists of a signal peptide, mature IGF-I, and an E-
peptide. To express the E-peptide natively, we decided to keep all of the elements of pre-
pro-IGF-I in order for the ordinary processing that produces free E-peptide to occur. 
However, expressing the IGF-I isoforms as a method of increasing E-peptide production 
also increases IGF-I. IGF-I induces many growth effects in muscle, and thus it is 
impossible to distinguish E-peptide activity from IGF-I activity when testing wildtype 
constructs. To overcome this problem, we mutated IGF-I at Valine 44 to Methionine (21), 
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effectively making the IGF-I non-functional, while still retaining its 3-D structure and 
pro-protein processing.  
There was a concern that mature IGF-I V44M could act as a dominant negative 
IGF-I and have negative growth effects. The overexpression of a non-functional IGF-I 
that still binds to IGF-I binding proteins (21), could compete with wildtype IGF-I for 
those binding proteins, or not allow wildtype IGF-I to bind to the IGF-IR. Alternatively, 
ISt V44M high expression could still lead to IGF-I-like effects, since IGF-I V44M can 
have up to 10% the activity of wildtype IGF-I (21). To account for both of these potential 
problems, we included two controls. First, we injected control mice with ISt V44M in 
one limb, and left the other limb untreated. With these mice, we compared the uninjected 
limb to the ISt V44M injected limb to determine if ISt V44M had any negative or IGF-I-
like growth effects. In all parameters studied, ISt V44M had no significant effect 
compared to uninjected limbs. To further control for potential dominant-negative effects, 
for every test vector, we injected each mouse with the test isoform AAVsc in one limb, 
and ISt V44M in the control limb. In this way, if IGF-I V44M had any effects, both limbs 
express IGF-I V44M, and thus the only difference between the two limbs is the E-
peptide. Using this study design, we can confidently say that IGF-I V44M expression has 
no affect on skeletal muscle in vivo, and that all effects reported are E-peptide dependent. 
The AAVsc-V44M vectors lead to robust expression of IGF-I isoforms in muscle 
(Figure 3-2). However, by ELISA, the ISt V44M isoform produced ~10-fold more IGF-I 
than IA or IB V44M. Since we injected the same number of vectors into each limb, the 
large difference in expression levels implies that the muscle can produce mature IGF-I 
more efficiency than pro-IA or -IB. More likely, however, is that the ELISA recognizes 
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mature IGF-I better than the pro forms (41). This is supported by our immunoblot results, 
where the mature IGF-I band is not 10-fold more intense than the pro forms using an 
IGF-I antibody (Figure 3-2 B). 
The EA domain has two asparagines residues that can be glycosylated (6). Thus, 
the EA peptide can come in three forms: unglycosylated, singly glycosylated, and doubly 
glycosylated. Consequently, pro-IA V44M has three different bands when 
immunoblotted with an IGF-I antibody (Figure 3-2 B-C). The ELISA shows less IGF-I in 
IA than IB V44M expressing muscles. However, this could be due to the glycosylation 
impeding antibody binding. In this study, it is unclear if glycosylated or non-glycosylated 
EA has more activity. In the future, non-glycosylatable IA V44M must be tested, to see if 
EA activity is different with and without carbohydrate side groups. 
 While our initial intention was to study the effects of free E-peptides, it is unclear 
if the IA or IB V44M activity is due to free EA/EB, or EA/EB still bound to IGF-I V44M 
in the pro form. When injected muscle lysates were subjected to immunoblotting for EA 
or EB antibodies, the free E-peptides (3-6 kDa) were not seen. This could be because the 
overexpression overwhelms cell processing machinery, and thus the pro forms are 
secreted before proprotein convertases can cleave away the E-peptide (22). Alternatively, 
the levels of free E-peptides could be below the limit of detection, either because it is 
difficult to immunoblot small proteins, or because the E-peptides are quickly degraded or 
not sequestered in the muscle cells. Recently it has been suggested that pro-IA is stored in 
the extracellular matrix outside of muscle fibers (53). Accordingly, it could be that pro-
IA or IB are sequestered inside or outside the muscle fibers, while the mature IGF-I and 
free E-peptides are released into the circulation, or quickly degraded. We previously 
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observed that EB is degraded very quickly in cell culture media containing FBS (Chapter 
II), and so the degradation of EB preventing free EB peptide detection is likely. However, 
we do not believe that the prevalence in pro-forms in muscle via immunoblot is V44M-
specific, as some endogenous IGF-I and wild-type IGF-IA expressed via AAVsc 
injection remains in the pro-form (41). Thus, it is unclear if the reported activities are due 
to free E-peptides, or if the E-peptides have activity while still attached to IGF-I V44M. 
Either way, mature IGF-I V44M is non-functional, and the test limbs were compared to 
limbs expressing ISt V44M. Therefore we can conclude that the results observed are E-
peptide specific, whether the activity is due to free E-peptides, or E-peptides bound to 
non-functional IGF-I 
Rodent E-peptide signaling has been studied in myoblasts (43) (Chapter II) and 
cardiomyoblasts (52). Both EA and EB have been shown to increase P-ERK1/2, but not 
P-Akt in serum-starved conditions. When IGF-I is added to myoblasts, which activates 
both MAPK and PI3K/Akt pathways, both EA and EB increase P-ERK1/2 further, but do 
not increase P-Akt (Chapter II). The E-peptides enhance MAPK signaling in an IGF-IR 
dependent manner, which complements our findings that E-peptides activity in vivo 
requires functional IGF-IR (Figure 3-4 and Table 3-1). The in vivo signaling results 
support this model, as in muscles that contain, produce, and secrete IGF-I, the expression 
of IA and IB V44M increases P-ERK1/2. In addition, IB V44M expression decreases P-
Akt levels, further suggesting that the E-peptides affect muscle signaling and could be 
tuning the IGF-IR towards MAPK. However, even though both E-peptides increased P-
ERK1/2, only IB V44M expression led to muscle hypertrophy. Further, the PI3K/Akt 
pathway is most commonly linked to muscle hypertrophy, and IB V44M expression 
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decreases its activation. Hence the connection between signaling and hypertrophy is not 
clear. 
 We observed muscle hypertrophy, and specifically MHC2B myofiber 
hypertrophy, in AAVsc IB V44M injected muscles. The change in mass was modest (5-
6%, Figure 3-4). However, it is close to the documented increase in hypertrophy after 
injection with AAV vectors harboring wildtype IGF-I isoforms (6-8%) (8). IGF-I is 
considered a master regulator of muscle growth, and so it is remarkable that EB can 
induce more than half the hypertrophy of wildtype IB.  
The increase in mass after IB V44M expression is due to an increase in fiber size, 
and specifically in MHC 2B fiber size (Figure 3-4,5&6). However, it is inconsistent that 
the mass of the EDL muscles increase by 5%, while the average fiber area increases by 
20%. The length of the muscles did not change (data not shown) and it seems unlikely 
that the density of the muscle could be altered enough to lead to this difference. However, 
IGF-I treatment often has varying effects on mass vs. myofiber hypertrophy. While 
increased local expression of IGF-I leads to both enlarged muscle mass and fiber area 
(38), systemic delivery of recombinant IGF-I into wildtype mice leads to no significant 
change in muscle mass, but a 55% increase in average fiber area (34). The disconnect 
between mass and myofiber hypertrophy after IGF-I treatment is curious, but it is clear 
that IB V44M expression induces both mass and fiber hypertrophy. 
Expression of the E-peptides also led to changes in the strength of the muscles. 
EDLs injected with AAVsc IA V44M were slightly but significantly stronger in specific 
force. This suggests that although there was no hypertrophy, somehow the architecture of 
the muscle was altered to increase the strength of the myofibers. IB V44M hypertrophy 
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after 1 month was coupled with a rise in maximum tetanus force, but after 3 months, both 
the tetanus and specific forces were reduced. This implies that long-term expression of 
EB has detrimental effects on muscle architecture, although there was still hypertrophy. 
There is a similar effect in mice lacking myostatin, a muscle growth inhibitor. Muscles 
from myostatin null mice are much larger than wildtype muscles, but there is a reduction 
in muscle strength, coupled by an increase in 2B fibers and depletion of mitochondria (3). 
While we did not see an increase in the proportion of 2B fibers (data not shown), we did 
observe an increase in 2B fiber size. Since EB hypertrophy preferentially affected 2B 
fibers, the reduction in IB V44M muscle strength could be a result of physiological 
stresses associated with dysregulated fiber hypertrophy (3). 
Additionally, myostatin-null muscles have reduced strength due to large 
myonuclear domains, meaning that each nucleus in the muscle supports a large amount of 
muscle-cell cytoplasm (47). The addition of extra nuclei, driven by satellite cell 
activation, is necessary to maintain strength in hypertrophic muscles. This problem is 
likely to occur in the IB V44M expressing muscles, since we saw a reduction in satellite 
cell number, and an increase in muscle size. It must be difficult for the remaining satellite 
cells to maintain the hypertrophic muscles. However, both IA and IB V44M expressing 
muscles had reduced satellite cell number, but only IB V44M muscles were weaker after 
3 months. Therefore, the reduction in satellite cell number cannot be the sole factor for 
the decrease in strength. 
Perhaps the most surprising finding from this study is that the E-peptides have no 
affect on muscle cell proliferation, and instead reduce satellite cell number (Figure 3-7). 
MGF/EB has been reported to activate satellite cells and increase their proliferation (4, 
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28, 37, 56), and so we expected the E-peptides to increase satellite cell number, increase 
the number of proliferating satellite cells, or increase the number of proliferating 
myoblasts. However, we saw no difference in the number of proliferating nuclei. How 
can EB increase myoblast proliferation in cell culture, but reduce their number in vivo? 
Perhaps the E-peptides do activate the satellite cells, and increase their proliferation, but 
this leads to a depletion of the stem cells. This could happen if the satellite cells, which 
have a finite number of times that they can divide, are overly activated like in many 
diseased muscle models, or the E-peptides could prevent satellite cells from reentering 
quiescence and satellite cell self renewal. Satellite cell activation, depletion, and self-
renewal in regards to E-peptide expression are projects currently being investigated in our 
lab. 
There has been a great deal of focus on MGF/IB/EB and sarcopenia. IB 
expression is reduced in aged muscle as is satellite cell number, suggesting that the 
reduction of this IGF-I isoform affects satellite cells, and could be used as therapy for the 
age-related muscle wasting (27). While IA expression can return normal function to aged 
muscle (12), we found that IB expression does not lead to hypertrophy in aged muscles 
(8), and so IB or EB may require an activated satellite cell pool to have activity. 
However, this study shows that EB expression leads to a reduction in satellite cell 
number without affecting proliferation. Therefore, it appears that aging muscle would not 
benefit from increased EB expression. Instead it may necessary for IB expression to be 
low in aged muscle, to not further the depletion of satellite cells. Expression of IA is also 
reduced in aged muscle, and thus although IGF-I itself could help sarcopenia, the E-
peptides may be working in opposition to IGF-I. 
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The E-peptides may not be a viable therapy for sarcopenia due to the reduction of 
satellite cells, and most likely will not maintain muscle mass in diseased, immobilized, or 
wasting muscle, as IB V44M expression cannot prevent glucocorticoid-induced atrophy.  
In this study, we report that EB is more potent than EA at inducing hypertrophy. 
However, long-term treatment might be detrimental as IB V44M expression for 3 months 
led to a reduction in muscle strength. Further, we found that the E-peptides require IGF-
IR in muscle to induce hypertrophy and increase strength. In order to harness the growth 
promoting affects of the E-peptides without also including their detrimental effects, we 
must better understand their activity in muscle, and how this activity affects IGF-I 
signaling. 
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Materials and Methods 
IGF-I V44M plasmids  
IGF-I constructs included the sequence to encode the class I signal peptide, IGF-I, and 
either EA (IA), EB (IB), or no peptide (ISt). For ISt, a stop codon was inserted at the end 
of the mature IGF-I. All cDNA constructs were inserted into the NheI and XhoI 
restriction sites of pCMV.IRES.eGFP vector (Clontech, Mountain View, CA, USA) as 
previously described (40).The plasmids were mutated at Valine 44 to Methionine by site-
directed mutagenesis (QuikChange II; Stratagene, La Jolla, CA, USA). The IGF-I V44M 
constructs were then sub-cloned into pAAVsc-CB plasmids for vector generation. 
Viral injections 
All experiments were approved by the university animal care committee. Recombinant 
self-complementary adeno-associated virus serotype 2/8 (AAVsc) vectors expressing the 
IGF-I V44M isoforms under the control of the chicken β-actin promoter were generated 
by the Children's Hospital of Philadelphia Vector Core. Viral injections of 1 x 1011 
particles diluted in 100 µl of phosphate-buffered saline (PBS) were performed into the 
anterior compartment of one lower hindlimb of anesthetized C57Bl/6 (C57) and MKR 
(25) mice targeting the tibialis anterior (TA) and extensor digitorum longus (EDL) 
muscles. For IA and IB V44M injected mice, the right limb was injected with ISt V44M 
to serve as a contralateral control. In addition, some mice were injected with ISt V44M in 
one limb and needle-prick only (no injection) in the other to serve as controls for ISt 
V44M activity. After injection, mice were housed in the animal facility until time of 
analysis. Mice were 2–3 weeks of age at the time of injection. They were sacrificed 7 
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days, 1 month, or 3 months after injection. The TA muscles were dissected and rapidly 
frozen in liquid nitrogen for biochemical analysis, while the EDL muscles were subjected 
to force measurements.  
Cell culture transfection 
1.2x106 3T3 cells were grown in 6-well plates (Falcon, BD Bioscienses, Sparks, MD, 
USA) in DMEM media containing 10% Fetal Bovine Serum and supplemented with 
100U/mL ampicillin and 100 U/mL streptomycin. Transient transfection was performed 
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). For each transfection, cells 
were mixed with 0.5 mL of Opti-MEM (Invitrogen) containing 6 µg of plasmid DNA 
plus 8 µl of Lipofectamine, and then 1.5 mL DMEM plus 10% FBS was added, and the 
cells were incubated for a total of 4 h. Cells were switched into minimal media (DMEM 
medium supplemented with 100U/mL ampicillin and 100 U/mL streptomycin) for 24 h 
after transfection. Controls included transfection of empty vector (green fluorescent 
protein, GFP). The next day, media from transfected 3T3 cells was utilized in kinase 
receptor activity (KIRA) assays (described below). 3T3 cells pellets were also retained 
for GFP immunoblot to determining transfection efficiency.  
IGF-IR Activation Assays  
To determine if E-peptides directly activate IGF-IR, a KIRA assay was preformed as 
previously described (21)(Chapter II). Briefly, 2.5x104 P6 cells, which overexpress IGF-
IR (a kind gift from the Baserga lab (45)) were seeded into 96-well plates. The cells were 
starved for 6 hours, and then treated with 3T3 conditioned media from the IGF-I isoform 
transfections (see above) for 15 minutes. Cells were lysed and IGF-IR was captured onto 
an ELISA plate coated with an antibody to IGF-IR (MAB1120, Millipore, Billerica, 
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MA). An HRP-conjugated antibody to phosphorylated tyrosines (16-454, Millipore) and 
TMB substrate (N301, Thermo Scientific, Rockfort, IL) was used for colorimetric 
quantification. Absorbance was read at 450 nm via the SpectraMax M5 plate reader 
(Molecular Devices, Sunnyvale, CA), which served as an indicator of IGF-IR 
phosphorylation.  
IGF-I ELISA  
Total IGF-1 content in muscle protein extracts was determined by a standard sandwich 
ELISA protocol using commercially available kit (MG100, R&D Systems) according to 
manufacturer’s recommendations and as previously described (8, 40). This kit detects 
total rodent IGF-I and there is no cross-reactivity or interference with IGF-II or IGF 
binding proteins. The assay can detect IGF-I at 30–2000 pg/ml, with an intra-assay 
precision of 4.3% and an inter-assay precision of 5.9%. Data were acquired in duplicate 
using a SpectraMax M5 plate reader (Molecular Devices, Sunnyvale, CA) at 450 nm and 
the results were averaged.  
Analysis of muscle contraction 
Mice were anesthetized with ketamine/xylazine and exsanguinated. The extensor 
digitorum longus (EDL) muscles were removed and placed in a bath of Ringer’s solution 
gas-equilibrated with 95% O2/5% CO2. The tendons were attached to a rigid post and to 
an isometric force transducer in a bath of Ringer’s solution, and the muscles were 
subjected to isolated muscle mechanical measurements using a previously described 
apparatus (Aurora Scientific, Aurora, ON, Canada) (10). After determining optimum 
length using single supramaximal twitch stimulation, maximum isometric tetanus was 
measured in the muscles from both limbs. Cross-sectional area (CSA) was calculated as 
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in (14). After force measurements were completed, the muscles were removed from the 
bath, blotted, weighed, pinned at optimum length, surrounded by OCT embedding 
compound (TissueTek), and rapidly frozen in melting isopentane. Muscles were stored at 
-80°C for subsequent analysis. 
Immunoblotting 
Tissues were removed from liquid nitrogen storage and homogenized in modified RIPA 
lysis buffer (50 mM Tris·HCl pH 7.4, 1% w/v Triton X-100, 0.25% sodium 
deoxycholate, 150 mM NaCl, 1 mM PMSF, 1 µg/ml aprotinin, 1 µg/ml leupeptin, 1 
µg/ml pepstatin, 1 mM NaVO4, 1 mM NaF, 1 mM EGTA). Extracts from transfected 
cells were obtained by cell lysis in the same RIPA buffer. Tissue homogenates and cell 
lysates were centrifuged to pellet debris, and the total protein was measured in the 
supernatant using the Bradford procedure (Bio-Rad protein assay, Hercules, CA, USA). 
Equal amounts of protein were subjected to SDS-PAGE using 16.5% Tris/Tricine or 
12.5% Tris/Glycine gels and transferred to polyvinylidene fluoride membranes 
(Immobilon-P, Millipore, Bedford, MA, USA). The following primary antibodies were 
used for the immunodetection: IGF-I (AF791; R&D Systems, Minneapolis, MN); EA 
(described in Chapter II); EB (44); GAPDH (sc-32233, Santa Cruz Biotechnology, Santa 
Cruz, CA); phospho-Akt (no. 9271), phospho-ERK1/2 (no. 9101), total ERK1/2 (no. 
9102), and GFP (no. 2955) (Cell Signaling, Beverly, MA). Membranes were washed in 
5% milk-TTBS and incubated with horseradish peroxidase-conjugated secondary 
antibodies. Protein detection was performed using enhanced chemiluminescence (ECL) 
substrate (Western lightning-ECL, PerkinElmer, Waltham, MA, USA), X-ray film 
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(Kodak) or  the ImageQuant (GE Fairfield, CT) detection system. Analysis of band 
intensity was performed using the associated image analysis software.  
Immunohistochemistry 
Frozen cross-sections (10 µm) from the midbelly of EDL muscles were stained for 
laminin (rabbit Ab-1; Neomarkers, Fremont, CA, USA) or dystrophin (VP-D505 Vector 
Laboratories, Burlingame, CA) to outline the muscle fibers. Fibers were typed with 
antibodies recognizing myosin heavychain (MHC) 2A (SC-71), MHC 2B (BF-F3), and 
MHC 1/β (BAF-8) (Developmental Studies Hybridoma Bank, University of Iowa, Iowa 
City, IA, USA). Satellite cells (Pax7; MAB1675, R&D Systems, Minneapolis, MN) and 
proliferating nuclei (Ki67; ab15580, Abcam, Cambridge, MA) were also stained. Nuclei 
were counterstained with DAPI. Stained sections were visualized on a Leica DMR 
microscope (Leica Microsystems,Wetzlar, Germany), and digital images were analyzed 
using OpenLab software (Improvision, Coventry, UK). Myofiber area was measured in 
all of the fibers in each EDL (~1000 fibers) at 100X magnification. 
Glucocorticoid atrophy 
Mice were injected with AAVsc IB and ISt V44M as described above. Two weeks later, 
the mice were treated with Dexamethasone (DEX; D2915 Sigma, St. Louis, MO, USA) 
as described previously (7). Dex was added to the drinking water at 0.03 mg/ml for 14 
days. Effectiveness of treatment was verified by measurement of body and spleen weight, 
which decrease with glucocorticoid treatment. 
Statistical Analysis 
All data were analyzed via student t-tests (paired and unpaired), or 1-way ANOVA 
followed by a Tukey post-test. Statistical significance was accepted at p < 0.05.  
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Model for E-peptide/IGF-IR interactions 
 I have collected data concerning rodent IGF-I E-peptides, their activity in 
myoblasts, their effects on skeletal muscle in vivo, and their functions through IGF-IR. 
From these results, I conclude that the two rodent E-peptides, EA and EB, have similar 
functions, although different potencies, and that both E-peptides utilize IGF-IR. My data, 
along with the results from another study in our lab, has led to the development of a new 
model of E-peptide-IGF-IR signaling modulation, which I describe here. I propose that 
the E-peptides bind to IGF-IR and that this binding increases the potency of IGF-I to 
activate IGF-IR, but tune the downstream signaling towards MAPK. I would like to stress 
that this model has not been fully validated, and there are many other possibilities as to 
how the E-peptides could affect IGF-IR and downstream signaling. However, I believe 
this model will be useful by providing a framework for future E-peptide experiments. 
 
Synthetic E-peptides affect IGF-IR and downstream signaling  
 When cultured myoblasts are treated with exogenous IGF-I, IGF-I binds to the α-
subunits of an IGF-IR homodimer. Ligand binding causes a conformational change in the 
receptor leading to autophosphorylation on the intracellular β-subunit tails. The activation 
of IGF-IR initiates two major downstream signaling pathways. The MAPK pathway, 
including ERK1/2, increases myoblast proliferation, while the PI3K/Akt pathway 
enhances myoblast fusion and subsequent myotube protein synthesis (3) (Figure 4-1 A). 
When the E-peptides are added to cells in the presence of IGF-I, the E-peptides further 
increase IGF-IR phosphorylation and MAPK signaling (Figure 4-1 B). We believe that 
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the E-peptides are modulating IGF-IR signaling via binding to a region on the 
extracellular face of IGF-IR that is not in the IGF-I ligand binding region. E-peptide/IGF-
IR binding may also result in a conformational change, which leads to the MAPK 
pathway being stimulated more than the PI3K/Akt pathway, therefore tuning IGF-IR 
downstream signaling.  
 Much of this model is corroborated by another study in our lab which focuses on 
pro-IGF-IA. Pro-IA treatment leads to more IGF-IR phosphorylation than mature IGF-I, 
suggesting that IGF-I is more potent at receptor activation when still attached to EA. The 
data is very consistent with my findings. Adding EA and IGF-I in the KIRA assay caused 
a ~30% increase in receptor phosphorylation compared to IGF-I alone (Figure 2-4), and 
when pro-IA and mature IGF-I are tested via the KIRA assay at equal molarity, pro-IA is 
40% more potent that mature IGF-I (13). IB was not tested, but likely behaves similarly, 
as EB also increased IGF-IR phosphorylation in the presence of IGF-I (Figure 2-4). 
Consequently, we believe that while the IGF-I in pro-IGF-I binds to the IGF-I ligand 
binding site on IGF-IR, the E-peptide can also bind to its binding region on IGF-IR 
(Figure 4-1 C).  
 While our lab has confirmed that pro-IA is more potent than mature IGF-I at IGF-
IR activation, downstream signaling has not yet been evaluated. We do not know if 
MAPK is favored over PI3K after pro-IGF-I stimulation. This experiment is important to 
confirm our model that pro-IA or pro-IB tunes IGF-IR signaling towards MAPK, the 
same way that the synthetic E-peptides do. We have IGF-I isoform constructs in which 
the protease cleavage site between mature IGF-I and the E-peptides is mutated, and these 
constructs only produce pro-IGF-I. We can transfect these constructs, along with the 
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wildtype ISt construct, into 3T3 cells and collect the conditioned media from the cells as 
we did in Figure 3-2. Instead of using the media for KIRA assays, as has already been 
done (13), we could use the conditioned media to stimulate C2C12 cells, and look at 
ERK1/2 and Akt phosphorylation of pro-IA or pro-IB treated cells compared to ISt 
treated cells. 
 Initially, we believed it unlikely that the E-peptide in pro-IGF-I could bind IGF-
IR when IGF-I is also bound. However, studies looking at the position of the C-terminal 
region of mature IGF-I show that this region, the site where the E-peptide would be 
attached, is not involved in IGF-I/IGF-IR binding. In fact, when a polyethylene glycol 
(PEG) group is attached to IGF-I where the E-peptide would be, the large PEG group still 
allows IGF-I/IGF-IR binding (9). We speculate that the small E-peptide protruding from 
IGF-I when it is bound to IGF-IR can still bind to its binding site and modulate IGF-IR 
downstream signaling. 
 In culture, our model is validated by two controls. First, in myoblasts when the 
IGF-IR receptor kinase activity is inhibited via NVP (Figure 2-3), the E-peptides can no 
longer increase MAPK signaling, showing that E-peptide MAPK stimulation is IGF-IR 
dependent (Figure 4-1 D). Also, in the KIRA assay, when no IGF-I was added, the E-
peptides alone did not increase receptor activation (Figure 4-1 E). 
There is a difference in results between IGF-IR receptor activation in C2C12 
experiments and KIRA assays using P6 fibroblasts (Figure 2-2,3&4). When analyzing 
downstream signaling, C2C12s were treated with synthetic E-peptides in serum-free 
media, and the E-peptides increased P-ERK1/2 in an IGF-IR dependent manner with and 
without exogenous IGF-I. However, in the KIRA assays, the E-peptides only increased 
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receptor activation when IGF-I was also added. Our model asserts that E-peptide-
associated increases in IGF-IR activation require the presence of IGF-I. The results from 
C2C12 cells are inconsistent with our model, as we did not add IGF-I with the E-
peptides. However, there was likely IGF-I present in the cell media. The cells were 
starved in serum-free media overnight, but muscle cells produce and secrete IGF-I. 
Therefore, 16 hours later, there was likely a large amount of IGF-I in the cell media and 
potentially sequestered in the extracellular matrix around the myoblasts. Accordingly, I 
observed that if I washed out the wells with serum-free media before treating with E-
peptides, the pERK signal was greatly dampened, and that the difference between NoTx 
and EA treatment was not as apparent (lab observation, data not shown). The situation is 
likely different for the KIRA assay, which used P6 fibroblasts. These cells are only 
starved for 6 hours, allowing less time for IGF-I secretion, and also fibroblasts secrete 
very little endogenous IGF-I (see below). 
 
IGF-I V44M isoforms utilize IGF-IR for activity in vivo 
 Our model is consistent with the results from AAVsc IGF-I V44M isoform 
injections. When IGF-I is added or overexpressed in skeletal muscle, IGF-IR is activated, 
leading to increased MAPK and PI3K/Akt signaling. MAPK and PI3K/Akt both lead to 
muscle hypertrophy, as MAPK stimulates activated satellite cells to proliferate, leading to 
more nuclei, while PI3K/Akt signaling stimulates myoblast differentiation and protein 
synthesis, leading to larger fibers (Figure 4-2 A). Both IA and IB V44M expression lead 
to increased MAPK signaling, without increasing P-Akt. It is possible that the free E-
peptides cleaved away from pro-IGF-I V44M act like synthetic E-peptides in culture and 
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modulate wildtype IGF-I activation of IGF-IR (Figure 4-2 B). While we observed 
increased MAPK signaling in both IA and IB V44M expressing muscles, we have not yet 
examined IGF-IR phosphorylation in these muscles, which is a critical experiment to 
conduct.  
Free E-peptides cleaved from pro-IGF-I V44M can certainly act like synthetic E-
peptides in culture and augment IGF-IR downstream signaling in the presence of 
wildtype IGF-I (Figure 4-2 B). Nevertheless we observed that most of the IGF-I produced 
from AAVsc IGF-I V44M injections is in the pro-IGF-I form, and most of the E-peptides 
produced remain attached to IGF-I. One mechanism for how the E-peptides could still 
augment IGF-I signaling while attached to a non-functional IGF-I is diagrammed in 
Figure 4-2 C. The E-peptide is not affected by the V44M mutation, and thus would still 
likely bind to IGF-IR. If there is enough flexibility in the region between mature IGF-I 
V44M and the E-peptide, than a wildtype mature IGF-I could still bind in its ligand 
binding site on IGF-IR with a pro-IGF-I V44M also bound at the E-peptide binding 
region.  
One result from the IGF-I V44M study initially did not fit our model. The V44M 
conditioned media from transfected 3T3s did not show increased IGF-IR phosphorylation 
compared to ISt V44M conditioned media (Figure 3-1). However, this experiment likely 
did not include the necessary wildtype IGF-I, since 3T3 cells do not produce a significant 
amount of IGF-I. Hence there was little to no IGF-I in the treatment media, which is a 
requirement for the E-peptides to augment IGF-IR signaling. We performed an IGF-I 
ELISA on the conditioned media from the V44M 3T3 transfection study, and the 
conditioned media from the 3T3 cells transfected with the control GFP vector only 
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secreted 2 pg/ml IGF-I into the media. This concentration of media is ~0.26 pM , which 
is far below the threshold of KIRA sensitivity, and thus we would not expect the E-
peptides to have any effect on IGF-IR activation. 
We surmised that the E-peptides affect IGF-IR signaling in vivo because IB 
V44M caused no hypertrophy, nor did IA V44M increase muscle strength, in MKR mice 
that do not express functional IGF-IR in muscle. While this control confirmed that a 
functional IGF-IR is necessary for E-peptide activity in vivo, it does not confirm that the 
E-peptides work with wildtype IGF-I to modulate IGF-IR signaling. To further verify this 
model, the V44M isoforms must be tested in IGF-I free muscle (Figure 4-2 E). We are 
currently breeding mice that lack IGF-I expression specifically in skeletal muscle, and are 
planning to inject these mice with the AAVsc IGF-I V44M isoforms. If the E-peptides do 
not have activity in these muscles, it will lend evidence to our model that the E-peptides 
modulate IGF-IR signaling but only in the presence of wildtype IGF-I. 
We realize that there are alternative mechanisms for IGF-I V44M action in vivo 
(Figure 4-2 G). One potential mechanism is that the E-peptides increase the binding 
affinity of V44M IGF-I for IGF-IR. We do not think this possibility is likely, however we 
should test this mechanism, as well as test pro-IGF-I V44M’s ability to activate IGF-IR. 
To assess how pro-IGF-I V44M activates IGF-IR, we can mutate IA and IB V44M at the 
E-peptide cleavage site, so that all of the IGF-I produced is in the pro-form. Then, the 
constructs can be transfected into 3T3 cells, and the conditioned media can be utilized in 
KIRA assays, with and without recombinant IGF-I added. If the pro-IGF-I V44M 
isoforms do not activate IGF-IR, then all of the activity observed in Chapter III must be 
due to free E-peptides cleaved away from IGF-I V44M isoforms. If the pro-IGF-I V44M 
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isoforms activate IGF-IR without wildtype IGF-I present, then Figure 4-2 G may be 
valid, in that the mutated IGF-I could have enough activity to activate IGF-IR. Most 
likely, the pro-IGF-I V44M isoforms will increase IGF-IR activation compared to ISt 
V44M only when IGF-I is added, exemplifying the necessity for wildtype IGF-I to be 
present for E-peptides to have activity, and demonstrating that the E-peptides still 
attached to IGF-I have activity. 
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Figure 4-1. Model of IGF-IR dependent E-peptide signaling. A-E. E-peptides affect 
IGF-IR signaling in cell culture. A. Normal conditions when IGF-I is added to myoblasts, 
activating IGF-IR, and leading to increases in MAPK andPI3K/Akt signaling. B. 
Synthetic E-peptides bind to the IGF-IR receptor, and when IGF-I is present, increase 
receptor activation and tune downstream signaling towards the MAPK pathway. C. The 
IGF-I in pro-IGF-I can still bind to IGF-IR, and then the E-peptide can likely bind and 
modulate IGF-IR. In another study from our lab, we found that pro-IGF-I is more potent 
than mature IGF-I at IGF-IR activation, but the consequences on downstream signaling 
are unknown. D. E-peptide MAPK activation is inhibited via NVP AEW541, an IGF-IR 
inhibitor. E. E-peptide IGF-IR augmentation requires IGF-I in P6 IGF-IR-overexpressing 
fibroblasts.  
 
Figure 4-2. Model of IGF-IR dependent E-peptide signaling in vivo. A. Normal 
conditions when IGF-I is added to or overexpressed in skeletal muscle, leading to 
increases in MAPK andPI3K/Akt signaling, which in turn leads to hypertrophy. B. Free 
E-peptides cleaved away from IGF-I V44M bind to the IGF-IR with wildtype IGF-I, may 
increase IGF-IR phosphorylation and tune the receptor towards MAPK, leading to 
hypertrophy. C. pro-IGF-I V44M may bind to IGF-IR in the E-peptide binding region, 
and still allow wildtype IGF-I to bind and activate IGF-IR, leading to enhanced MAPK 
activation and hypertrophy. D. E-peptides have no affect on hypertrophy when the IGF-I 
receptor is non-functional, as in MKR mice. E. Predicted: In IGF-I-null muscles, the E-
peptides cleaved from IGF-I V44M or pro-IGF-I V44M cannot increase IGF-IR 
signaling. F. Mature IGF-I V44M (IStop) does not activate IGF-IR downstream 
signaling. G. An alternative model for IGF-I V44M function. The E-peptides may modify 
the IGF-I/IGF-IR interaction enough to allow IGF-I V44M binding, and the non-
functional IGF-I V44M could have gain some function, leading to enhanced MAPK 
signaling and hypertrophy. 
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Discussion and Future Directions 
 Data from Chapter II indicate that when IGF-I and free E-peptides are present, 
there is an increase in IGF-IR on the cell membrane. This could be one way that the E-
peptides increase IGF-IR phosphorylation: by increasing IGF-IR availability. Do the E-
peptides increase IGF-I phosphorylation solely by increasing IGF-IR on the cell surface? 
The IGF-I/IGF-IR binding alternation induced by E-peptide binding may also trigger the 
receptors to recycle quickly to the cell membrane. In a previous study, we saw that the E-
peptides increased IGF-I uptake, presumably through receptor-mediated endocytosis. The 
E-peptides are also internalized, possibly by IGF-IR internalization (12). Accordingly, 
the E-peptides binding to the IGF-IR could mediate receptor internalization, and also 
IGF-IR recycling or recruitment to the cell membrane. To see if the E-peptides can 
increase IGF-IR phosphorylation without affecting localization, we must perform an in 
vitro receptor kinase assay, where IGF-I receptors are isolated and purified, E-peptides 
are added to the cell-free solution including free IGF-IR, and IGF-IR phosphorylation is 
measured by ELISA or immunoblotting. If the E-peptides, in the presense of IGF-I, 
augment IGF-IR phosphorylation in vitro, then changing the localization is not the 
mechanism. 
 Many previous studies have blocked IGF-IR signaling using neutralizing 
antibodies to the receptor, and showed that MGF/EB can still have activity (1, 10, 11, 14, 
16, 17). Our model may help to explain why a neutralizing antibody to IGF-IR could 
have no affect on E-peptide activity. Potentially, the E-peptides bind to a region of IGF-
IR, and modulate how IGF-I binds to its receptor. If this is true, then the E-peptide 
modification to IGF-IR may alter or block the neutralizing antibody epitope, thus 
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preventing antibody binding. Thus, the receptor would behave as if there was no 
neutralizing antibody, IGF-I could still bind to the receptor, and the E-peptides could still 
augment IGF-IR signaling and downstream effects. Alternatively, neutralizing antibodies 
sometimes lead to receptor internalization (2). If the E-peptides are internalized with 
IGF-IR, then they may still have this activity, even when an antibody is bound. Then, 
they could still increase receptor recycling or recruitment to the cell membrane. Instead 
of using neutralizing antibodies, we utilized an IGF-IR kinase inhibitor in cell culture 
(Figure 2-3 & 2-5), and mice lacking functional IGF-IR in muscle (Figure 3-4 and Table 
3-1), and demonstrated that E-peptide activity relies on IGF-IR signaling. 
 While we have shown that E-peptide treatment leads to enhanced IGF-IR 
phosphorylation, we do not know the specifics of where the receptor is phosphorylated. 
Since we observe divergent downstream signaling, it could be that the E-peptides lead to 
specific phosphorylations which favor MAPK over PI3K/Akt pathway activation. IGF-IR 
can be phosphorylated at multiple sites, and E-peptide augmentation may favor certain 
sites. Further studies should be conducted to tease apart the importance of IGF-IR 
modifications after E-peptide stimulation. 
How does myoblast differentiation fit into this model? The effects of MGF/EB on 
differentiation have been contested. While most studies claim that MGF/EB delays or 
inhibits differentiation (15, 17), other studies show that MGF/EB is a positive regulator 
of differentiation. Adding a stabilized synMGF to human primary muscle cultures can 
enhance fusion and myotube hypertrophy (6), and depleting IB in C2C12 myoblasts 
delays differentiation (8). In Chapter II, we show that synthetic EA inhibited 
differentiation, while EB did not. However, we also saw that EB degraded quickly, and 
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thus likely was not stable for long enough to continually affect differentiation. However, 
EB delaying differentiation is consistent with our in vivo V44M data, because IB V44M 
expression reduced Akt phosphorylation, and the PI3K/Akt pathways is known to 
regulate differentiation. IA V44M expression did not decrease Akt phosphorylation, but it 
did increase MAPK signaling. If both E-peptides delay differentiation, then it could be 
due to IGF-IR signaling favoring MAPK to PI3K/Akt signaling. 
 The free E-peptides or the E-peptides included in pro-IGF-I isoforms could affect 
the on/off rates of IGF-I/IGF-IR binding, which in turn could affect receptor downstream 
signaling. In fact, the result that MAPK is stimulated while PI3K/Akt is not after E-
peptide treatment suggests that the there is a change in the kinetics of receptor-ligand 
interaction, which has a greater impact on activation of the PI3K/Akt pathway than on the 
MAPK pathway (5). The PI3K/Akt pathway is more sensitive to changes in IGF-I/IGF-
IR binding, and this could explain why the E-peptides utilize IGF-IR, but favor MAPK to 
PI3K/Akt signaling. 
While we observe a changes in IGF-IR downstream signaling after IA and IB 
V44M expression, linking IGF-IR modulation and satellite cell depletion is difficult. 
Satellite cells in their quiescent state do not express IGF-IR, and do not until they are 
activated (4). Therefore IGF-I does not itself activate satellite cells, nor could the E-
peptides work via IGF-IR signaling augmentation to activate the cells. Accordingly, it is 
unclear how or if the E-peptides affect satellite cell number via IGF-IR signaling 
modulation, but they could affect the cells after they are activated. If this is the case, then 
the E-peptides may stimulate the satellite cells, via IGF-IR, to proliferate via MAPK 
signaling. Somehow, though, the number of satellite cells decreases, either by depletion, 
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or prevention of satellite cells re-entering quiescence. It has been shown that satellite 
cells, once activated, divide asymmetrically into one cell destined to remain a stem cell, 
and one cell that will become a myoblast, proliferate, and differentiate (7). The E-
peptides may affect this process, and this should be a focus for future studies. 
Additionally, mice injected with the V44M isoforms should be analyzed for proliferating 
satellite cells early after injection, to see if there is an initial increase in satellite cell 
number and proliferation. The mice injected with AAVsc V44Ms for 3-months should 
also be analyzed for Pax7 and general muscle architecture, to see if there is a further 
depletion of satellite cells, and to see if there is any damage that could explain the 
reduction in force (Table 3-1). Futhermore, mice that do not have an activated satellite 
cell pool, like aged mice, could be injected to see if the E-peptides have any effect on 
mice without activated satellite cells. 
 It is also difficult to explain how both EA and EB can have similar signaling 
effects, but that these changes do not lead to the same changes in biology. Both E-
peptides increased MAPK signaling and augment IGF-IR phosphorylation in cell culture, 
but only EB increased myoblast proliferation and migration. Since EA was much less 
potent at ERK1/2 phosphorylation, and proliferation and migration seemed to increase 
with EA treatment, but not reach significance, it may be that EA acts similarly to EB, but 
is simply less potent. This is akin to our in vivo results, where both IA and IB V44M 
expression led to increased MAPK signaling and decreases in satellite cell number, but 
only IB caused hypertrophy. By 3 months after injection, however, IA V44M expressing 
muscles were larger in mass and CSA than controls, but again, the results were sub-
significant. Thus, we believe that in vivo as well, EA is simply less potent than EB. We 
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are currently testing more mice at the 3 month time point, to see if EA really can increase 
hypertrophy if given enough time. If EA can cause hypertrophy, then perhaps EA would 
be a better choice for therapy, since it does not cause the same decrease in muscle force 
associated with IB V44M expression.  
 One difference between cell culture experiments utilizing synthetic E-peptides 
and in vivo expression of IGF-I V44M isoforms, is that synthetic EA has no 
glycosylation, while over half of IA V44M produced in muscle is glycosylated (Figure 3-
2). We have found that pro-IA containing glycosylation does not activate IGF-IR as well 
as non-glycosylated IA (13). So, it may also be true that EA is more functional when not 
glycosylated. IA V44M expression may not have promoted as much hypertrophy as IB 
V44M because less than half of the EA expressed was in the functional non-glycosylated 
form. 
Surely there are crucial experiments that must be performed to validate our 
model. First, to confirm that the E-peptides augment IGF-IR phosphorylation in the 
presence of IGF-I, synthetic E-peptides with and without IGF-I must be added to isolated 
IGF-IR in vitro. For V44M studies, pro-IA and IB V44M mutated to block E-peptide 
release must be tested via KIRA assays, to prove that the pro-V44M forms can act like 
free E-peptides. In addition, the regular V44M isoforms should be tested via KIRA 
assays with and without IGF-I, to demonstrate that the V44M isoforms require wildtype 
IGF-I to modulate IGF-IR signaling. Further, we must measure the degree of IGF-IR 
phosphorylation in IA and IB V44M expressing muscles. The major experiment 
necessary to verify our model would test if the E-peptides physically bind to IGF-IR. The 
lab is currently investigating the binding affinities of E-peptide/IGF-IR and pro-IGF-
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I/IGF-IR interactions. If the E-peptides do bind IGF-IR, then it would be interesting to 
determine where the binding occurs, and also if the activities of other growth factor 
receptors are modulated by small peptides. This model is an important first step in 
mapping out and understanding E-peptide activity through IGF-IR, and will be a valuable 
framework while planning and evaluating further experiments concerning the E-peptides, 
their activity, and ways of modulating IGF-I signaling potency. 
 
E-peptide signaling is muscle-specific 
 To show that the E-peptides affect MAPK and IGF-IR signaling, multiple cell 
types were treated with the E-peptides, leading to confounding results. Originally, we 
found that fibroblasts that do not contain IGF-IR (R- cells) do not respond to the E-
peptides. This result showed that E-peptide signaling was IGF-IR dependent. However, it 
was important to also show that IGF-IR positive fibroblasts, like 3T3 cells, respond to the 
E-peptides as myoblasts do, with increases in ERK1/2 phosphorylation. However, the 
IGF-IR positive fibroblasts did not respond to E-peptide treatments with increased 
MAPK signaling as in myoblasts (Figure 4-3). Additionally, the 3T3 cells did not 
respond to IGF-I by increasing P-ERK1/2, which implied that 3T3s cells did not express 
IGF-IR, or that IGF-I signaling was fundamentally different in fibroblasts.  
 To examine this result, multiple cell types were treated with IGF-I, and IGF-IR 
levels, phosphorylation, and downstream signaling were analyzed (Figure 4-4). The 
results showed that the different cell types had dramatically different responses to IGF-I 
treatment. First, the 3T3 cells expressed high levels of IGF-IR, comparable to C2C112 
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myoblasts, and so IGF-IR expression did not cause the lack of IGF-I response. However, 
while IGF-I treatment led to a robust phosphorylation of IGF-IR in the 3T3 cells, there 
was no detectable response in the C2C12 myoblasts. Also surprising, the non-observable 
IGF-IR phosphorylation in the C2C12 cells led to robust ERK1/2 and Akt 
phosphorylation, while the robust IGF-IR phosphorylation in the 3T3 cells led to much 
less downstream activation. From these data, it is clear that the fibroblasts and myoblasts 
have very different signaling responses to IGF-I. The 3T3s may have a dampening effect 
after IGF-I stimulation, where downstream amplification is inhibited by phosphatases or 
degradation. Alternatively, myoblasts may contain more scaffolding proteins or upstream 
kinases that lead to enhanced downstream signaling. Either way, the results are clear that 
the downstream ERK phosphorylation after E-peptide treatment is muscle-specific, and it 
would not be useful to use fibroblasts to investigate downstream IGF-IR signaling via E-
peptides. Accordingly, rodent E-peptide signaling has only has been published in muscle 
cells (14, 16)(Chapter II). While Goldspink and his colleagues originally proclaimed 
MGF/EB/IB to be muscle and stretch specific, we were dubious, since IGF-IB is 
expressed in many cell and tissue types. However, it may be that the activity of the E-
peptides, especially in modulating IGF-IR signaling, is a muscle-specific.  
 These results raise an obvious question: Why are signaling responses to IGF-I 
different in various cell types, and what is the significance that the E-peptides only 
modulate IGF-IR signaling in muscle cells and tissue? Thus far, only myoblasts and 
cardiomyoblasts have been published to respond to the E-peptides with increased P-
ERK1/2 (14, 16)(Chapter II), but other cell types must be evaluated to determine if and 
how they respond to IGF-I and E-peptide treatment. The cell type specificity of IGF-I 
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signaling raises many questions and will lead to a new project concerning different cell 
signaling responses to IGF-I and the E-peptides. It will be useful to determine how and 
why cell-types respond and signal differently after IGF-I and E-peptide treatment, as 
IGF-I has endocrine function and affects many cell and tissue types. While the E-peptides 
have been studied extensively in muscle, it is possible that other tissues have similar or 
different responses to the E-peptides, and the responses of these tissues must be 
understood before we can fully comprehend E-peptide activity. 
  
 Figure 4-3 
 
Figure 4-3. E-peptide signaling in IGF
Synthetic EA (1µM), EB (10nM), Media containing 10% FBS, or recombinant IGF
(10nM) were added to fibroblast media for 20 minutes. Neither EA, EB, or IGF
treatment had any effect on P
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Figure 4-4. IGF-IR and downstream signaling activation with and without IGF
treatment. IGF-IR null (R
myoblasts were treated with serum
20 minutes.  
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